Podcasts about pcrs

Rapamycin is changing what's possible in fertility treatment, and in this episode, I'm breaking down exactly how. Originally discovered in the soil of Easter Island and long used by the longevity community to extend healthspan, rapamycin is now showing real promise for improving egg quality, increasing blastocyst formation rates, and helping women over 40 (even over 45) get pregnant.  Joining me is Dr. Steve Palter, founder and medical and scientific director of Gold Coast IVF in Woodbury, New York. We cover the science of how it works at the cellular level, the landmark placebo-controlled trial out of China that gave us published data for the first time, my own case series accepted to PCRS, and how I'm now using Rapamycin for egg freezing patients, not just last-resort IVF cases. We also get discuss the Vibrant Trial on ovarian aging, dosing protocols, and why resistance training and protein intake matter for fertility and longevity.  In this episode, we cover: • What rapamycin is, where it comes from, and why it's become the darling of the longevity world • How rapamycin may improve egg quality by regulating protein synthesis and cellular repair in aging ovarian cells • The landmark placebo-controlled trial out of China showing significantly higher pregnancy rates in poor-prognosis patients • My own case series (including patients over 45 getting pregnant) accepted to PCRS • Who is (and isn't) a good candidate, and how to have that conversation with your doctor • Why dosing protocols are still evolving and what current regimens look like • The underrated role of resistance training and protein intake for fertility, PCOS, and longevity Read the full show notes, and find the full length episode here. Resources: Dr. Steve Palter on Instagram, TikTok & Facebook: @StevenPalterMD Gold Coast IVF: goldcoastivf.com Dr. Palter's PCOS metabolic reset program: pcosbaby.com Follow Dr. Aimee & The Egg Whisperer Show Subscribe to the audio podcast: https://open.spotify.com/show/5y9gPpZlUZT33eLMU90TYB Subscribe to the video podcast:  @EggWhisperer   Website for Newsletter, Consult: https://draimee.org/ Do you have questions about IVF? Join Dr. Aimee for The IVF Class at The Egg Whisperer School. The next live class call is on Monday, July 13, 2026 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Subscribe to my YouTube channel for more fertility tips!Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Fertility & Sterility on Air comes to you from the Pacific Coast Reproductive Society 2026 Annual Meeting in Rancho Mirage, CA! Join our host Pietro Bortoletto as he moderates a Fertility & Sterility Fellow Debate: Gestational Carrier Use Without a Medical Indication at the 2026 PCRS Annual Meeting. Fellows Anthony Bui, Bahar Yilmaz, and Jensen Reckhow argue on the pro side, while Howard Li, Francesca Barrett, and Adriana Wong make a case for the con side. View Fertility and Sterility at https://www.fertstert.org/  

Advances in immunotherapies for multiple sclerosis and related disorders have increased the risk of infections and raised important questions about vaccination efficacy. This episode reviews infection risks across treatment classes, emphasizes the importance of monitoring and patient education, and discusses optimal vaccine timing to preserve protective immune responses. In this episode, Aaron L. Berkowitz, MD, PhD, FAAN, speaks with Avindra Nath, MBBS, FAAN, coauthor of the article "Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Dr. Nath is the chief of the Section of Infections of the Nervous System at the National Institute of Neurological Disorders and Stroke, National Institutes of Health, in Bethesda, Maryland Additional Resources Read the article: Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Full episode transcript available here Dr Berkowitz: Over the last decades, there has been a revolution in the treatment of multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic conditions with countless new, highly effective medications. However, with every new treatment comes new risks; and in the case of immunomodulatory therapy, many of those risks relate to infection. Today, I have the privilege of talking with an expert on this topic, Dr Avindra Nath, about the infectious risks of treatments for multiple sclerosis and other immune-mediated neurologic disorders.  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Berkowitz: This is Dr Aaron Berkowitz, and today I'm interviewing Dr Avi Nath about his article on vaccine considerations and infection risk in multiple sclerosis and related disorders, which he coauthored with Dr Amit Bar-Or. This article appears in the April 2026 Continuum issue on multiple sclerosis. Welcome to the podcast, Dr Nath, and could you please introduce yourself to our audience?  Dr Nath: Thanks very much for inviting me to this podcast. I'm absolutely delighted to have the opportunity to discuss our areas of interest and expertise related to infections and vaccinations for MS patients. My area has been studying the infections of the nervous system since the beginning of the AIDS pandemic, and over the years and decades, we've developed expertise related to various types of CNS infections. That includes ones that are developing in individuals who have immune compromise due to a variety of different reasons. Dr Berkowitz: Fantastic. Well, glad to have the opportunity to speak with you today. When I was in medical school---and you were my attending, actually, we were just reminiscing, which we probably think was not that long ago, but is now over twenty years ago---there were just two medications for MS, right? Beta interferon and glatiramer acetate. And now we have over a dozen, and it's amazing to think of all the progress in these last two decades, as well as for related diseases like NMO. I don't think we even had the aquaporin-four biomarker, right, when I was working with you as a med student in the early 2000s. Dr Nath: And that certainly dates me a lot.  Dr Berkowitz: Both of us.  Dr Nath: Yeah.  Dr Berkowitz: Of course, with all these new treatments, these have been amazing advances for our patients, right? But these come with new treatment-related risks to monitor for with the immunomodulatory medications for MS and related disorders. And one of those most important risks is that of infection. So, your article reviews the potential infectious complications of medications used to treat MS, NMO, etc, and also covers considerations related to thinking about vaccines in this patient population. So, as the MS treatment landscape grows, I can say as a general neurologist, keeping up with all these medications and what to screen for and what to worry about and when to vaccinate just becomes more challenging every year. And your article has so many helpful tables, some organized by medicine, some organized by- sorry, medication, some organized by infection, some by vaccines. So, this is gonna be a great resource for our providers to print out and tape up in their clinic rooms. We won't be able to get into all the depth and detail that you have in this article today, but I do want to focus on some of the key points here related to the common medications we use for MS and which infections to think about and which vaccine considerations we might need to keep in mind for these medications. But before we delve into the drugs, I just wanna ask you more broadly, you talk in the article about the challenge of patients with immune-mediated diseases who are on immunomodulatory therapy being at risk for both flares of their disease and for infections; and these infections can present somewhat atypically, right, in immunomodulated hosts, to maybe coin a term you can correct me on, because they can't mount the full inflammatory response. So how do you approach new symptoms in patients on these immunomodulatory medicines as far as distinguishing disease flare from a treatment-related infection?  Dr Nath: So, I have to say that although a lot of new treatments have come along for MS, and they've really, you know, improved the outcome tremendously and there are so many different options, it has also kept people like me relevant because they cause a lot of various types of infections, and so keeps me in business all the same. But just as you mentioned, there's so many of them, even I have difficulty keeping track of what does what. So, you do need to be able to refer back to published literature, and the tables, I hope, will be quite useful in that regard. You're absolutely right, and you can get new infections, you can get reactivation of existing infections, and you can get atypical presentations of various types of infections that you may not normally think of. So that presents multiple challenges to the treating physician. The other interesting thing about MS is, just as you mentioned, that you already have CNS lesions to begin with. Now, on top of it, you have an infection, so now how to sort out what is the existing disease and what is the infection, it can again become challenging. But one thing is for sure: all these infections are caused by an organism. So, what you really need to do is, the underlying diagnostic is to demonstrate the presence of the organism. Whether you demonstrate it depending on the infection in the spinal fluid or in the brain or, you know, some peripheral organ system, that is going to be key to making the diagnosis. So, all your clinical acumen is good, but that alone may not be sufficient. Dr Berkowitz: Very good. So, when you see a, a patient now who has a new neurologic symptom in the context of an immune-mediated disease who's on immunomodulatory therapy, what goes through your mind? Are you thinking this disease and this drug, and sort of what are the infections, and does the syndrome match? Or are you thinking, you know, you can't always rely on the imaging to distinguish between, say, a flare of an MS and PML because white matter lesions could look similar? How do you sort of approach this scenario when it comes up?  Dr Nath: So, you're right. You have to keep an open mind so that even though you know some infections are more likely to occur with certain types of medications, that doesn't mean that others cannot occur. So, I think when you first see the patient, you should not jump to conclusions, but rather have an open mind. But yes, for example, your patient is on natalizumab, the chances of PML are going to be high. It's a very interesting drug. It does not cause immune compromise in the periphery, but what it's doing is preventing these cells from getting into the brain. So, because then it's acting at the blood-brain barrier. So that means that organisms that are already present in the brain have an opportunity to get reactivated. Turns out you don't have a lot of organisms in the brain, except JC virus seems to be one of them that does somehow, in some individuals, manage to reside out there. And so that can get reactivated. It can get reactivated in the periphery and then enter the brain, too. So, where the very specific mutations have to occur in that virus in order to take residence in the brain. That would be a suspicion that you might have, and MRI can be useful in, again, helping you think about that possibility. If you have typical lesions involving the U fibers, they're demyelinating, usually you do not have much edema around them because patient is immune compromised, but certainly within the brain in these individuals. And so, then you need to demonstrate the organism. The demonstration of the organism should be in the spinal fluid and not in the blood because in the virus, it can-- is reservoir in the kidneys and in the lymph nodes, and periodically it'll shed into the blood. Detection of the organism in the blood can be a false positive, but in the spinal fluid, it shouldn't be there unless you have an infection. Or if you cause a traumatic tap, I guess, if a patient is viremic, that's a possibility, but those are extremely rare. So at least for PML, that's the way that you would diagnose it. Now, you can develop, for example, if an individual is on fingolimod, you can get a wide variety of infections. Here it's a totally different type of mechanism of action. Here the cells are trapped within the lymph nodes, so that means now your entire periphery is immune compromised, right?  So here you can get viral infections, bacterial infections, fungal infections. So here, if a patient presents with new neurological symptoms, you have to have a really open mind for all these possibilities. Now, let's say a patient was on dimethyl fumarate, and dimethyl fumarate causes neutropenia early on. So here you have to worry about an individual developing bacterial infections, so latent tuberculosis or bacterial meningitis can occur in these individuals. That's something to keep in mind. It's not that other infections cannot occur with dimethyl fumarate, you can see PML and other things too, but the chances of bacterial infections are greater. So, you got to make sure that you draw all the cultures for that purpose. Similarly, if you're on a complement inhibitor, like a C5 inhibitor or the thing that I could use in NMO, there are the chances of meningococcal meningitis. So, these patients, you need to prevaccinate them before you start these kinds of treatments and look for that possibility. When you suspect bacterial infections, particularly acute bacterial meningitis, there time is of essence. Also, in some of the acute viral infections, for example---herpes encephalitis is another one---you have to be so careful, and if you suspect any of them, even if they're with possibly atypical manifestations, you treat first and then diagnose later, and draw all your cultures, whatever you need to, and just treat them. And these infections can also cause cerebral edema, so one has to be careful about doing spinal taps in these individuals. You want some kind of neuroimaging before you do them. In the days when we didn't have neuroimaging, we used to say, "Okay, if your patient has focal neurological signs or is comatose, you don't do it." But these days, you can get imaging very quickly and very easily. All the-- Because of our stroke management, we've learned how to do them so quickly. So, I think there's little excuse not to do imaging and prevent herniation from occurring.  Dr Berkowitz: That's very helpful. So, using the information we know about the drug, and we're going to rapid-fire review some of that in a bit to know what infections the patient is susceptible to, but acknowledging that any patient can get any infection, right? Whether they're on particular medications or not. And then if you're not sure, based on the neuroimaging, which as you said, is helpful, but not always helpful in distinguishing between infections and flares or, as you said, in the case of meningitis, encephalitis, early on at least, especially in immunocompromised or immunomodulated, quote unquote, patient might not see the typical imaging. So really, when safe, getting CSF or cultures, PCRs, and other infectious studies too is really gonna be the definitive diagnostic maneuver here. Is that fair summary across the board?  Dr Nath: I think you said that absolutely right. And you summarized that correctly. And, you know, thing about infection, a lot of neurological diseases are, you know, diagnosed by clinical acumen, like your Parkinson's and Alzheimer's and others. Think about infections is caused by an organism, demonstrate the organism, right? That should be your goal. It doesn't mean that clinical acumen is not important, but here you have an opportunity to demonstrate the organism, so you should depend upon that.  Dr Berkowitz: Okay. Well, you gave us a nice segue by talking about some of the infections to worry about with some of the medications. So what I'd like to do now for the sort of second half of our interview here is to go through some of the more common medications used for MS, and if we have time, for NMO, and just sort of go kind of rapid fire here, and for each medication, if you can tell us the kind of top infectious concerns and whether when to consider them or what screening needs to take place before or during administration of the medication, and then any vaccine considerations we should be aware of. Some of these will obviously be quite short depending on the medicine. So, going back to the two medications I alluded to earlier that were the only ones in play when you and I last saw each other on the wards when I was a medical student, beta interferon, glatiramer acetate, any infections or vaccine considerations with these medications?  Dr Nath: No, I think they're probably your safest medications now as far as immunomodulatory therapies are concerned. These two, and IVIG, if you ever use them, are probably the safest, do not require any vaccine considerations, per se. Dr Berkowitz: Perfect. Okay. So, moving on to fingolimod and others in the sphingosine-one phosphate receptor modulator family, what are the infectious considerations? Any prescreening or vaccination considerations?  Dr Nath: I think all your patients should be prescreened for antibodies to JC virus, because there is a risk for PML, and those who are positive should be closely monitored. So, it's not an absolute contraindication for using these medications, but they just require closer monitoring. With this class of drugs, PML is of consideration. Also, these varicella-zoster virus infection, yeah, with that you can develop zoster encephalitis or myelitis. It can present with motor symptoms as well, which can be atypical. You don't usually see them otherwise in immune-competent individuals. So, varicella-zoster, sometimes you can develop encephalitis, also vasculitis with varicella-zoster, so one has to be careful. So, getting the shingles vaccine can be actually very helpful to prevent these things. And then some patients can even develop herpes simplex encephalitis also, and that can be extremely atypical. So, they don't- they can involve the basal ganglia, can involve the brain stem and cerebellum. So again, your index of suspicion should be very high. Interestingly, although HSV encephalitis has been associated with NMDA receptor encephalitis, those reports of NMDA receptor encephalitis have not been published yet with NMS patients. Not sure why, maybe they just have been missed. But that doesn't seem to be a major concern. And then there are a whole host of other infections that can occur with this class of drugs, and that can include toxo; fungal infections, particularly crypto. There's a case report of histoplasmosis; hepatitis virus, particularly hepatitis C; and then the poxvirus is a good example. You can get molluscum contagiosum; warts with papillomavirus; you can get atypical mycobacteria; and even Kaposi sarcoma, which is HHV8. So, there's a huge variety of infections with the sphingosine one phosphate receptor modulators.  Dr Berkowitz: And any- aside from screening for JC virus before initiating these, any- and then continuing to monitor for JC antibody index, any other considerations as far as labs to send, monitoring before or on the drug or vaccine considerations for patients on fingolimod and the others in this category, siponimod, etcetera?  Dr Nath: Yeah, there are a lot of things to consider. All the details are really available in the chapter if you look at them. But briefly, all the things that one could potentially vaccinate patients for, all these infections I mentioned, one should do so. The timing is critical so that if you can do it before treatment, I think, before starting treatment, that is absolutely important. And you got to give them at least, you know, two to three weeks for these vaccines to take effect before starting your medication. If your patient already arrives on a medication, then you got to play this game of you know, before the next dose, give them again two to three weeks before the next dose and start vaccinating them and get all the vaccines in. Broadly, about the things to worry about the vaccines are you have live vaccines, and you've got the inactivated vaccines or the subunit vaccines. You have to be careful with live vaccines, because if your patient is immunocompromised, that virus can sometimes itself cause harm. For example, you know, yellow fever is one, and there you can develop encephalitis from it. Measles, mumps, rubella, these are all live vaccines. Now, the good thing is that a lot of us have been immunized very early in childhood, but that may not be the case any longer. And so, these things, one has to be very careful with when you're giving live vaccines, that we want to avoid them as much as possible, and individuals are gonna be immune-compromised. But all the others, meningococcus, for example, you should- the HPV vaccines, the varicella zoster vaccines, all these things, you've got to pre-vaccinate and make sure that they have an antibody response to them before starting immunocompromising therapy. Dr Berkowitz: Perfect. Okay, moving on to some of the other orals. What infectious and/or vaccine considerations do we have with teriflunomide?  Dr Nath: Okay, yeah. Teriflunomide is a very interesting drug. It's relatively safe. There is concern about the possibility of varicella zoster infection, people have reported that, and also tuberculosis. But PML is extremely rare, if not at all, and we haven't seen herpes encephalitis quite yet.  Dr Berkowitz: Got it. How about dimethyl fumarate? Dr Nath: Yeah. So dimethyl fumarate is... as I mentioned earlier, it's interesting because it causes this neutropenia. It's transient, but it occurs early on, and these patients can be at risk of PML, although small. They can develop varicella zoster virus infection, herpes encephalitis, and also fungal infections. For example, cryptococcal infection has been reported with dimethyl fumarate. Dr Berkowitz: Okay. We've spoken a bit about natalizumab and PML, and you have extensive information on this in your article, and I'll defer the reader to that. But for natalizumab, what are the key points every neurologist should know about natalizumab and PML as far as from the practical perspective, screening, frequency of screening, when to worry, when to not use natalizumab at all in the first place based on what you find in your screening for JC virus? What are the key points every neurologist should know?  Dr Nath: Uh, yes. You bring up an important point, and that is all patients should be monitored for JC virus. If they're JC virus-negative, so that's your most ideal patient to go on natalizumab, but that doesn't mean they cannot get infected with the virus. In fact, there's an interesting study claiming that, you know, patients, when they get these infusions, they're all sitting in the same room getting infused. Some have JC virus, some don't have JC virus, and so there's the potential that we may be aiding the transmission here in some way or another. The virus is an interesting one. It comes out in urine, and then it's spread through oral contamination, gets into the tonsils, and then spreads from there to your marrow and resides in the kidney and the marrow, as well as the lymph nodes, forever. So, you, you have to monitor these patients to see that during the course, even if they're negative, they could turn out positive. So, every six months or a year, an antibody test should be done on all patients irrespective. If a patient already has antibodies, that's not an absolute contraindication. It just means you've got to monitor them closely for development of new symptoms, and if, whenever there are new symptoms, don't just assume this is due to MS, but just make sure the MRI is done with and without contrast. The- and if there's still a suspicion, that you do a CSF evaluation for JC virus. Just detecting, looking for JC virus in the blood, a rising titer is another thing that can help you. And so, the titer is also important. And the reason you have rising titers is it means that there's an infection that's already occurred in the brain, and the immune system is reacting to that infection by increasing titers. But that alone is not sufficient to make the diagnosis. You still- that gives you an index of suspicion. You've got to then do the MRI and the spinal tap to, you know, be absolutely certain. So, each patient is a little bit different, so the way you monitor them is going to depend on where they are. You know, if they've had prior immunomodulatory therapy before starting natalizumab, or if they're on natalizumab for more than two years, then the chances of PML are much greater, so you may want to monitor them more closely. Uh, they never had any prior immunomodulatory therapy, you're just starting natalizumab, maybe once a year is sufficient. So, I think you've got to tailor it depending on what your risks are for each patient. Dr Berkowitz: Perfect. That's very helpful. And again, you write extensively about PML and natalizumab and PML considerations in your article. So, for a more detailed and in-depth discussion of what we just discussed, definitely hope readers will take a look at your article. Okay. Last but not least---certainly not least, 'cause we're using these probably, it seems, the most commonly in many places I've worked---rituximab, ocrelizumab are B-cell therapies for MS. What are some of the infectious and vaccine considerations related to these infusion medications?  Dr Nath: So, there's concern for PML with anti-B-cell therapies also, maybe not to the same degree as natalizumab, but the same principles should be applied. A lot of people think that these are relatively safe. I don't think so. I think we see enough number of patients on B-cell therapies with PML. So, I would use the same caution because these infections are... you know, can be fatal. So, one should be very careful, even with anti-B-cell therapies. And just with natalizumab, you also have the risk of VZV infection causing shingles. HSV1 has been reported, but there's another interesting complication that has been reported with anti-B-cell therapies, and that is severe West Nile encephalitis. And as mosquitoes-borne diseases are getting more and more prevalent, and we're seeing West Nile cases erupting every summer, I think one's got to be, you know, very cognizant of the fact that this can occur. These patients should take precautions to prevent mosquito bites from occurring and not expose themselves to areas where they could be at risk for it. Unfortunately, there is no vaccine for it and no specific treatment for West Nile. So, all one can do is use prevention strategies for mosquito bites.  Dr Berkowitz: Yeah, I'm glad you mentioned that. I think the only really truly severe neuroinvasive cases I've seen of West Nile virus have indeed been in patients who were being treated with B-cell therapy. Not, if I'm remembering correctly, for immune-mediated disease, but for a lymphoma, so probably other confounding factors there. But yeah, it's a disease we learn about and think about, but I've only seen the most severe cases in patients who had abnormal immune systems, so I'm glad you flagged that. This has been a very helpful discussion, and I've learned a lot from you. I learned a lot from your article, just as I did when you were my attending some 20-something years ago on the wards when I was a medical student. So, it's good to continue learning from you through your writing and research, and today from getting to talk to you again. I encourage our readers to read your article and to bookmark those tables for when these considerations come up for your patients on these immunomodulatory therapies and you're wondering which infections to worry about and how to manage vaccines in this patient population. So again, today I've been interviewing Dr. Avi Nath about his article on vaccine considerations and infection risk in multiple sclerosis and related disorders, which he wrote with Dr. Amit Bar-Or. This article appears in the April 2026 Continuum issue on multiple sclerosis. Be sure to check out Continuum Audio episodes from this and other issues, and thank you again to our listeners for joining today.  Dr Nath: Thank you so much, Aaron, for that wonderful interview, and I'm extremely proud of all your accomplishments over the last 20 years. You've done an amazing job, and it was such a pleasure to see you and to be able to do this interview with you. Thank you again.  Dr Berkowitz: Thanks. That means a lot. I never would have imagined- we won't say 20, how many, but 20-something years ago as the medical student looking up to you and all your expertise on these infections and all of your research that led to so much of our understanding on these, that I would find myself interviewing you two decades later. So, for all the students listening, you never know where you'll end up, but I appreciate your very kind words.  Dr Nath: That's what we hope for all our students. Thank you so much.  Dr Berkowitz: Thanks again.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Anoche hubo Clásico Barcelona-Madrid y coincidió por primera vez con la consecución de un título de Liga, conseguido por los blaugranas. Fuera del fútbol, Estados Unidos notifica un caso positivo de hantavirus asintomático en uno de los ciudadanos repatriados desde Tenerife. Otro estadounidense evacuado presenta síntomas compatibles con la enfermedad, al igual que un pasajero francés que fue repatriado ayer; según ha comunicado el primer ministro del país. Los 14 españolas ya se encuentran en cuarentena en el hospital militar Gómez Ulla. En Andalucía, el PP acaricia la mayoría absoluta gracias al estancamiento de VOX y al descenso del PSOE, según el sondeo de 40db para La SER y EL PAÍS. Moreno  podría gobernar en solitario aunque con dos escaños menos de los que tenía, mientras que Montero empeoraría los resultados de los socialistas de 2022. Donald Trump rechaza la respuesta de Irán a su propuesta de paz.  Medios estadounidenses apuntan que Teherán ha exigido reparaciones de guerra, el levantamiento de las sanciones y el control sobre el estrecho de Ormuz. Y esta semana declaran los últimos testigos en el juicio del caso Kitchen antes de escuchar los audios de Villarejo. La jornada de hoy empezará con el interrogatorio a un ex alto cargo de Interior, Juan Rueda Méndez y a varios agentes de policías.

La actualidad se centra en la crisis sanitaria, con los catorce españoles del crucero Ondius en cuarentena en el hospital Gómez Ulla de Madrid, donde se les realizan PCRs, mientras dos personas de ese barco dan positivo en sus países. En el ámbito judicial, la Audiencia Provincial de Asturias condena a los padres de la "Casa de los horrores" de Oviedo a dos años y diez meses de cárcel por violencia psíquica y abandono de familia. En deportes, el FC Barcelona celebra su vigesimonovena Liga, con un emotivo Hansi Flick tras ganar el título el día del fallecimiento de su padre. El Real Madrid analiza su temporada y surgen rumores sobre el posible regreso de Mourinho al banquillo. Además, la economía colaborativa gana terreno, con familias que alquilan bienes y espacios como piscinas para obtener ingresos extra, lo que plantea cuestiones fiscales y de seguros. Finalmente, Instagram elimina el cifrado de extremo a extremo en sus mensajes privados, permitiendo a Meta acceder a ellos, y se ...

Got a question?

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

L'apnée du sommeil se caractérise par des arrêts respiratoires répétés la nuit, souvent provoqués par la fermeture des voies aériennes (apnée obstructive). Les personnes concernées peuvent être des hommes ou des femmes, y compris après la ménopause, mais aussi des gens minces ou jeunes. De nombreux facteurs de risque existent : surpoids, âge, sexe, anatomie des voies aériennes, prise d'alcool, certains médicaments, et même la respiration buccale.Avant d'aller plus loin, nous aimerions vous inviter à découvrir Transforma, notre programme en ligne de perte de poids qui a été pensé tout particulièrement pour les femmes en périménopause et ménopause. Transforma, c'est un programme de 8 à 12 semaines qui vous enseigne comment optimiser votre santé métabolique tout en atteignant et en maintenant votre poids santé. Arrêtez de vous battre contre votre métabolisme, apprenez comment travailler avec lui! Rendez-vous sur www.transforma.fit.Les symptômes ne se limitent pas au bruit nocturne : somnolence diurne, troubles de la concentration et de la mémoire, irritabilité, baisse d'énergie, céphalées matinales, troubles de la libido et de l'érection sont fréquents. Chez l'enfant, l'apnée peut simuler un trouble de l'attention. L'apnée a aussi des répercussions sur la santé métabolique et hormonale. Elle augmente le cortisol, dérègle l'insuline, stimule l'appétit, fait baisser la testostérone et bouleverse, chez la femme, la production d'œstrogènes. Elle favorise la prise de poids et accentue la résistance à l'insuline.Le diagnostic se fait par questionnaire (Epworth ou STOP-BANG) et tests spécialisés (polysomnographie ou PCRS à domicile). Même une apnée légère peut altérer la vie quotidienne, augmenter les risques d'accidents, d'hypertension, de diabète, de troubles cognitifs et d'humeur.Les traitements incluent la pression positive continue (CPAP), la perte de poids, une bonne hygiène de vie, le traitement de la congestion nasale, la gestion du sommeil et même des solutions comme la thérapie positionnelle, l'orthèse mandibulaire ou la cétose nutritionnelle. Il existe aussi des astuces simples, comme l'application iRonfle pour dépister le ronflement.En conclusion, l'apnée du sommeil peut toucher tout le monde, même les enfants, et nécessite une prise au sérieux : il y a des solutions concrètes et efficaces pour améliorer la santé physique et mentale.Les messages clés de l'épisode sont : Les symptômes de la ménopause peuvent être très incommodants, et même engendrer de l'insomnie et de la dépression. Les bouffées de chaleur sont particulièrement problématiques, et environ 80% des femmes vont en avoir. La sévérité des bouffées de chaleur est associée à un risque accru de maladie cardiovasculaire, mais plus d'études sont nécessaires pour savoir si c'est un lien de cause à effet. Les palpitations cardiaques sont aussi fréquentes en périménopause et en ménopause et elles sont habituellement causées par la baisse de l'estradiol, mais mieux vaut consulter son médecin si on ressent des palpitations et ne pas simplement déduire que c'est les hormones. L'estradiol soutient la santé cardiaque en améliorant le profil lipidique, en réduisant l'inflammation et en maintenant la flexibilité des vaisseaux sanguins.L'hormonothérapie de remplacement, selon les études, semble être plus efficace pour prévenir les maladies cardiovasculaires que les statines, chez les femmes, mais à l'heure actuelle, en Amérique du Nord, on ne la recommande pas encore d'emblée pour prévenir la survenue de ces maladies. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

En el boletín de hoy también hablamos de: Granjas cerradas y sacrificios masivos… ¿otra coreografía conocida? Denuncian tráfico de órganos en la sombra. Solo un 14% de PCR detectaron infecciones reales. ⚖️ Europa podría cambiar sus propias reglas sociales. ✈️ ¿Nanopartículas desde aviones comerciales? Queremos saber tu opinión: ¿Te creíste en su momento lo que nos dijeron de los “PCRS positivos”? Comparte si intuyes que nada ocurre por casualidad. #NoticiasDeHoy #MindaliaDespierta #Conciencia #ControlGlobal #SaludReal

En el boletín de hoy también hablamos de: Granjas cerradas y sacrificios masivos… ¿otra coreografía conocida? Denuncian tráfico de órganos en la sombra. Solo un 14% de PCR detectaron infecciones reales. ⚖️ Europa podría cambiar sus propias reglas sociales. ✈️ ¿Nanopartículas desde aviones comerciales? Queremos saber tu opinión: ¿Te creíste en su momento lo que nos dijeron de los “PCRS positivos”? Comparte si intuyes que nada ocurre por casualidad. #NoticiasDeHoy #MindaliaDespierta #Conciencia #ControlGlobal #SaludReal

Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals and former malaria drug developer at Walter Reed, joins the Tick Boot Camp Podcast to unpack the science and strategy behind treating babesiosis. Drawing parallels to malaria, Dow explains why tafenoquine (brand: Arakoda), FDA-approved for malaria prevention, is being studied for Babesia, how coinfections (Borrelia, Bartonella) complicate care, and why chronic illness needs a different clinical approach. He previews an upcoming Mount Sinai trial for chronic babesiosis focused on fatigue outcomes and discusses real-world diagnostics using FDA-approved blood donor screening plus PCRs from Galaxy Diagnostics and Mayo Clinic. The conversation also touches on prophylaxis concepts, immune dysregulation, and building a clearer path from anecdote to evidence for the tick-borne disease community. Guest Geoff Dow, BSc, MBA, PhD CEO & Board Member, 60 Degrees Pharmaceuticals Background: Biotechnology (Perth, Australia), PhD in malaria drug discovery, decade at Walter Reed Army Institute of Research, MBA in the U.S. Leads clinical programs exploring tafenoquine for babesiosis. Key Topics & Takeaways Malaria ↔ Babesiosis Parallels: Both are red-blood-cell parasites; acute symptoms driven by red cell destruction. Similar drug targets justify testing some anti-malarials against Babesia. Why Tafenoquine (Arakoda): An 8-aminoquinoline that induces oxidative stress in RBCs; distinct mechanism from atovaquone + azithromycin combo (current standard for acute babesiosis), potentially useful for resistance management. Chronic vs. Acute Disease: Acute babesiosis in immunocompetent patients often responds to standard care; chronic illness remains under-defined and underserved. Coinfections Are Common: Many chronically ill patients present with Borrelia, Bartonella, and Babesia together; diagnostics and treatment need to acknowledge polymicrobial reality. Upcoming Clinical Trial (Mount Sinai): Population: Chronic babesiosis with disabling fatigue, plus Babesia symptoms (e.g., air hunger, anemia) and lab evidence in the last 12 months. Regimen: 4-day loading dose then 200 mg weekly of tafenoquine for 3 months. Outcomes: Patient-reported fatigue (quality-of-life) + monthly molecular testing (FDA blood donor test, Galaxy Diagnostics PCR, Mayo Clinic PCR) during treatment and 3 months post-therapy. Goals: Demonstrate symptom improvement, assess eradication signals, and validate accessible diagnostics against an FDA-accepted assay. Prophylaxis & Post-Exposure Ideas: Animal data suggest short-course tafenoquine can eradicate early Babesia; human prophylaxis trials face feasibility and regulatory hurdles. Diagnostics Gap: Need for standardized, sensitive tools to define chronic babesiosis and track response. This trial also serves as a real-world diagnostic comparison. Immune Dysregulation & IACI: Overlap among long COVID, ME/CFS, post-treatment Lyme—shared theme of immune dysregulation with possible persistent antigen stimulation. Safety Notes: G6PD deficiency is relevant to 8-aminoquinolines; established safety database exists for malaria prevention dosing—critical as studies expand to babesiosis. Notable Quotes “You've got to put some lines in the sand—run the trial, collect data, and move the field forward.” “The best we can do for chronic disease starts with defining it—and validating the diagnostics we use to track it.” “8-aminoquinolines offer a different mechanism than current babesiosis standards—key for resistance and combinations.” Resources Mentioned Arakoda (tafenoquine): FDA-approved for malaria prevention; under study for babesiosis. Diagnostics: FDA-approved Babesia blood donor screen; Galaxy Diagnostics PCR; Mayo Clinic PCR. Organizations & Events: ILADS, Global Lyme Alliance, tick-borne disease conferences. Research Partners: Mount Sinai (NYC), Tulane University (Bartonella/Borrelia collaboration). Who Should Listen Patients with chronic Lyme or chronic babesiosis symptoms (fatigue, air hunger, anemia) Clinicians seeking updates on Babesia treatment research and diagnostics Caregivers and advocates tracking IACI and immune dysregulation science Researchers exploring antimalarial repurposing for tick-borne diseases Call to Action Subscribe to Tick Boot Camp and share this episode with someone navigating chronic tick-borne illness.

Fertility & Sterility on Air is at the Pacific Coast Reproductive Society 2025 Annual Meeting in Indian Wells, CA! In this episode, our hosts Kate Devine and Micah Hill talk with: PCRS leadership Alexander Quaas and Jason Franasiak discussing this and future conferences (0:41), Shannon Rainsford about Protamine 2 deficiency (9:54), Andria Besser about mosaic and segmental PGT-A results (16:15), Emily Patterson about comprehensive carrier screening (28:35), Esther Chung about a low-cost progestin protocol for oocyte cryopreservation (32:23) and Howard Li discussing the feasibility of microwave drying for long-term storage of human oocytes at non-freezing temperatures (41:28). View Fertility and Sterility at https://www.fertstert.org/  

Our hosts, Dom and John, are excited to welcome special guest, Carrie Vyhlidal, to discuss the topic of the 80th episode of “The Weekly Bioanalysis” podcast – The Rapid Evolution of PCR Assays. PCR (or Polymerase Chain Reaction) is like a copying machine for DNA. Scientists have found ways to measure the copies being made throughout the reactions, which is where they get their real-time, quantitative PCR (or qPCR). Carrie does a wonderful job of explaining not only why these advancements in the study of PCRs are so amazing – but also why they play (and will continue to play) such an important part in bioanalysis.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

This week on Chasin' the Racin' podcast, Dom Herbertson & Josh Corner are joined in the trailer by the Moto2 American Racing team owner Eitan Butbul. He tells us how he went from a fan of the racing back in Israel to owning a team on the world stage, the costs of doing so, the challenges that come with it and of course we touch on the deal with Skinner's time with the team & how that came to an end. Enjoy - CTR x   Powered by OMG Racing  Supported by JCT Truck & Trailer Rental and Bennetts  Sponsor of the ep: PCRS - the Irish official Öhlins sales and services centre. They would like to use this episode to let everyone know there is going to be fundraiser for Anthony O'Carroll, who was involved in an incident at the Southern 100 this year as he is still in hospital over in Liverpool and his parents have been there with him since the accident. The fundraising event is happening in Ballyduff in Co Kerry Ireland on the weekend of September 13th-15th so get yourselves there if you're local and help raise some funds for the family in this difficult time.   If you're interested in sponsoring an episode of the podcast, please don't hesitate to get in touch via email to chasintheracin@outlook.com   ------------   If you would like to get a signed copy of Alan Carter's book please follow the following link below. It is currently UK shipping only but we are working away behind the scenes for it to be available worldwide - keep up to date on our socials to see when this becomes active!       Shop CTR merchandise & AC book: https://chasintheracin.myshopify.com     CTR Patreon Page: https://patreon.com/MotorbikePod?utm_...     -------------     SOCIALS:   Instagram: @chasintheracinpod   Facebook: Chasin' The Racin' Podcast   X: @motorbikepod

Dans l'épisode d'aujourd'hui, nous parlerons du lien entre la santé buccale et la santé métabolique. Il s'agit de notre premier épisode d'une série d'épisodes qui seront basés sur les conférences du Sommet virtuel de la santé métabolique 2024. Ces conférences sont encore disponibles à l'achat sur sommetmetabolique.com. Dre Roxane Katiya, qui est dentiste généraliste en pratique privée à Saint-Bruno-de-Montarville. Sa pratique englobe l'implantologie, la réhabilitation complète, l'apnée du sommeil et le ronflement. Dre Katiya est diplômée depuis 2006 de l'Université de Montréal et depuis 2007 de l'Université de Rochester, à New York.Sujets abordés :impact de la santé buccale sur la santé métaboliqueimportance du contrôle du diabète et hygiène dentairel'associations entre les bactéries orales et les maladies coronariennes, certains cancers, l'arthrite rhumatoïde et les accouchements prématurésmicrobiote buccal, une entité moins bien connuelien entre la parodontite et de l'impact des rince-bouches sur les maladies chroniqueseffets nocifs de la chlorhexidine sur le microbiome oralsyndrome de la bouche qui brûle importance de l'apnée et du ronflement en dentisteriecontroverse sur l'utilisation du fluor en dentisterieComment la santé buccale affecte-t-elle la santé globale métabolique?Les maladies parodontales peuvent vraiment affecter le corps, en particulier le cœur Les infections respiratoires L'ostéoporosePerte de dents  Le diabète entretient une relation bidirectionnelle avec la maladie parodontale Il y a aussi un lien entre la maladie parodontale et la polyarthrite rhumatoïde Les rince-bouche La Dre Katiya suggère : Biotène ou Terabreath et les pastilles Denta Mouth.  Le syndrome de la bouche qui brûle ou “burning mouth syndrome” en anglais. L'apnée du sommeil et le ronflement La Dre Katiya suggère d'utiliser l'application SnowLab qui permet aux individus de dépister s'ils ronflent. Le fluor, est-ce nocif pour la santé? C'est maintenant l'heure de l'astuce de la semaine : il faut écouter l'épisode pour la connaître!Messages clés : Premier message clé : la santé de la bouche a beaucoup plus d'impacts sur la santé métabolique qu'on pourrait le soupçonnerIl y a une association entre les mauvaises bactéries de la bouche, le tartre et l'inflammation, et les maladies cardiovasculaires, certains cancers dont le cancer du côlon, la polyarthrite rhumatoïde, les accouchements prématurés et les bébés naissants de petit poids, le diabète, la résistance à l'insuline, les maladies intestinales inflammatoires, les infections respiratoires et même la maladie d'Alzheimer. Il y a même un lien bidirectionnel entre le diabète et l'hygiène dentaire Tout comme nous avons un microbiote intestinal qui est de plus en plus reconnu comme étant notre 2e cerveau, nous avons aussi un microbiote oral et si celui-ci est en déséquilibre, avec trop de mauvaises bactéries par rapport aux bonnes, si on est en dysbiose, eh bien ça peut entraîner toutes sortes de problèmes de santé dans le reste du corps. Les rinces-bouche affectent négativement le microbiote oral. Le syndrome de la bouche qui brûle est un problème qui est plus fréquent chez les femmes en périménopause ou en ménopause. Le dentiste peut aider. L'apnée du sommeil et les ronflements peuvent relever de la dentisterie. L'utilisation du fluor dans l'eau ou dans les pâtes à dents pour prévenir les caries est un sujet controverséPour commander un test en ligne et le faire livrer chez vous : Test de sommeil à domicile pour dépistage d'apnée du sommeil (PCRS) - (centreaxis.ca)Pour obtenir un rendez-vous pour avoir une requête de dépistage d'apnée du sommeil : Rendez-vous - Traitement de l'apnée du sommeil - Somnos (cliniques-somnos.com) (exemple de clinique, il y en a d'autres au Québec qui offrent ce service)

Fertility & Sterility on Air brings you a deep dive into the June issue Seminal Contribution: a randomized controlled trial studying the use of progestins for ovulation supression in predicted high responders. With Micah Hill, Ernest Ng, and Zhi Chen. Read the article: https://www.fertstert.org/article/S0015-0282(24)00030-X/abstract View Fertility and Sterility at https://www.fertstert.org/  

Some old news is making the new news recently and is getting shared around the alternative circles. That PCR tests were 97% false positive! What does that mean and what did that change? ----- Get into Gold & Silver and out of the fiat trap below: https://7kmetals.com/drewweatherhead/ Get Tickets to the 2024 Parental Rights Tour with Dr. James Lindsay in Alberta: https://brushfire.com/anv Join the chat LIVE on Rumble for future Social Disorder Podcasts! https://rumble.com/user/SocialDisorderPodcast Get your edition of Layers of Truth at the links below: Audiobook: https://www.audible.ca/pd/B0D1VV75CM?source_code=ASSOR150021921000V Hardcover: https://shorturl.at/quLO7 Paperback: https://amzn.to/3U97tz5 Support the show one time or become an OFFICIAL Pattern Enjoyer by pledging to donate monthly below: https://www.buymeacoffee.com/drewweather Tell me what you thought of the show! Text me at: (587)206-7006 Get you copy of "Consciousness Reality & Purpose" on Amazon.com TODAY: https://www.amazon.com/dp/B0BS5FWLBK Subscribe to the Social Disorder Substack: https://thesocialdisorder.substack.com/ This episode is made possible by: DrewJitsu Online Jiu-Jitsu Coaching Sign up to get 2 week FREE to a library of over 750+ Brazilian Jiu-Jitsu Technique videos taught by your host - Drew Weatherhead! Hit the link below to get started today! https://drewjitsuonline.com/orders/customer_info?o=43849

Fertility & Sterility on Air brings you the highlights from the 2024 Annual Meeting of the Pacific Coast Reproductive Society, with interviews of presenters at PCRS 2024 in Indian Wells, CA! We had a chat with the winners of the PCRS Awards, as well as with authors of other very interesting studies evaluating a wide range of subjects in the field of reproductive medicine: determining the ploidy of abnormally fertilized embryos, predicting whether sperm will be obtained surgically in non-obstructive azoospermia, de novo oocyte creation from stem cells, and trialing needle-free IVF. We also take a deeper dive into the meeting with the president and incoming president of PCRS: Tamara Tobias and Alexander Quaas. View Fertility and Sterility at https://www.fertstert.org/

This episode of Inside EMS is brought to you by Lexipol, the experts in policy, training, wellness support and grants assistance for first responders and government leaders. To learn more, visit lexipol.com. In this episode of Inside EMS, cohosts Chris Cebollero and Kelly Grayson welcome Chief Gary Ludwig to the podcast. The group discuss imparting knowledge to new medics and Ludwig's latest book, “385 Things Veteran EMTs and Paramedics Can Teach You: Emergency Medical Technician and Paramedic Tips and Tricks of the Trade.” The book contains information on patient assessment, managing airways, starting IVs, penetrating trauma, crimes scenes and more. Chief Ludwig shares his experience with terrible PCRs, and why we should be teaching medics to write reports like our law enforcement partners. He shares tips like: Why you should always stay in the left lane How to avoid tipping stretchers Why to avoid abbreviations in PCRs For a signed copy, visit www.garyludwigbooks.com. About our guest  Gary Ludwig is a well-known author, educator, speaker, and consultant who has served in three fire departments over his career. His fire, EMS, rescue, 911 and emergency management career spans a total of 46 years, including 35 years in two metropolitan cities, St. Louis and Memphis. He has been a paramedic for over 44 years. He served as the president of the International Association of Fire Chiefs (IAFC) during the 2019-20 term, and was selected as the International Career Fire Chief of the Year in 2022. He has a master's degree in business and management.  He has written over 500 articles for professional fire and EMS publications and is the author of four books.  He has also been invited to speak at over 400 professional EMS or fire conferences or seminars. He has won numerous awards including the International Career Fire Chief of the Year in 2022, the James O. Page EMS Leadership Award in 2014 and the IAFC EMS Section's James O Page Achievement Award in 2018. He has managed two award-winning metropolitan EMS systems (Memphis and St. Louis) and was fire chief of an ISO Class 1 fire department (Champaign).  In 2022, he was appointed by FEMA Administrator Deanne Criswell to the National Advisory Council for FEMA.

This episode of Inside EMS is brought to you by Lexipol, the experts in policy, training, wellness support and grants assistance for first responders and government leaders. To learn more, visit lexipol.com. In this episode of Inside EMS, cohosts Chris Cebollero and Kelly Grayson welcome Chief Gary Ludwig to the podcast. The group discuss imparting knowledge to new medics and Ludwig's latest book, “385 Things Veteran EMTs and Paramedics Can Teach You: Emergency Medical Technician and Paramedic Tips and Tricks of the Trade.” The book contains information on patient assessment, managing airways, starting IVs, penetrating trauma, crimes scenes and more. Chief Ludwig shares his experience with terrible PCRs, and why we should be teaching medics to write reports like our law enforcement partners. He shares tips like: Why you should always stay in the left lane How to avoid tipping stretchers Why to avoid abbreviations in PCRs For a signed copy, visit www.garyludwigbooks.com. About our guest  Gary Ludwig is a well-known author, educator, speaker, and consultant who has served in three fire departments over his career. His fire, EMS, rescue, 911 and emergency management career spans a total of 46 years, including 35 years in two metropolitan cities, St. Louis and Memphis. He has been a paramedic for over 44 years. He served as the president of the International Association of Fire Chiefs (IAFC) during the 2019-20 term, and was selected as the International Career Fire Chief of the Year in 2022. He has a master's degree in business and management.  He has written over 500 articles for professional fire and EMS publications and is the author of four books.  He has also been invited to speak at over 400 professional EMS or fire conferences or seminars. He has won numerous awards including the International Career Fire Chief of the Year in 2022, the James O. Page EMS Leadership Award in 2014 and the IAFC EMS Section's James O Page Achievement Award in 2018. He has managed two award-winning metropolitan EMS systems (Memphis and St. Louis) and was fire chief of an ISO Class 1 fire department (Champaign).  In 2022, he was appointed by FEMA Administrator Deanne Criswell to the National Advisory Council for FEMA.

Back to the cut and thrust of clinical neonatology for the September 2023 Archimedes, where we visit the challenge of sugar-free babies again. How do you move forward with uncertainty about the adverse effects of medicines but significant problems with the adverse effects of disease processes? [doi 10.1136/archdischild-2023-325726]   We also flicker our minds back to the Olden Days, when analysers were simpler and viral PCRs were Special And Rare. And where Jones criteria were more in evidence than circulating IL23 levels. We ask - how does time change things? [doi 10.1136/archdischild-2023-326113]   We would love for you to be involved in Archi [adc.bmj.com/pages/authors/#archimedes] - just ask the questions that your patients are offering you - and tell us how you're fidning the podcast offerings.   Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832

This episode of EMS One-Stop With Rob Lawrence is brought to you by Lexipol, the experts in policy, training, wellness support and grants assistance for first responders and government leaders. To learn more, visit lexipol.com. Page, Wolfberg & Wirth was asked by the National EMS Information System (NEMSIS) Technical Assistance Center (TAC) to research frequently asked questions related to data in EMS patient care reports. PW&W analyzed these questions under applicable laws and guidance, and developed general answers and best practices contained in the new publication, “Patient Care Report Data QuickGuide - FAQs on owning, amending, retaining and sharing patient care report data.” In this week's EMS One-Stop, available in both video and audio versions, Host Rob Lawrence speaks with the PW&W authors of the project, Ryan Stark, managing partner, and Steve Johnson, director of reimbursement consulting. They discuss the guide, why it's needed, and the major FAQs and misconceptions about PCRs. The guide is broken down into four key areas of FAQs: PCRs' legal status Amending PCRs PCR retention Transferring PCR data Top quotes from this episode “I would much rather defend an organization who regularly goes through a quality assurance process, whereby they make the provider and hold them responsible for the accuracy and completeness of the record.” — Ryan Stark “Others may say, we see a lot of amendments to your records. The answer is ‘yes, that's because we care about getting it right' – that's the mantra of our organization.” — Ryan Stark “One of the things behind the importance of documentation is that it doesn't live in a vacuum. We are in a day and age where it's going to follow the patient for their lifetime, so you may have a rehab facility that wants to consult the medical record to determine the mechanism of injury or how the injury occurred and the only person [that knows that] is the EMS practitioner.” — Ryan Stark “Long gone are the days where we can give you a quick ticket, passing along the information to the receiving facility. Now we are marrying up records, electronic health exchanges and other mechanisms and the genesis of all this starts with the original call.” — Steve Johnson “Everyone should sign the patient care report. Why? Because everyone was a function of providing that particular service and we get a lot of pushback and they say ‘well now I'm legally responsible for everything that happened,' and that's not what the law says. The law says, for what you did, you are responsible for what you did and what you didn't do when you had a legal duty to do something or withhold doing something because it was contraindicated. All that indicates is that yes, I reviewed it and to the best of my knowledge it's true and accurate.” — Ryan Stark “The law will impose liability where it lands. Just because you've signed that particular patient care report, doesn't mean you're responsible for all the interventions and everything that I outlined in there, it would be whoever performed or withheld those interventions that would be responsible within the scope of practice.” — Ryan Stark Episode contents 1:09 – Introductions 1:30 – PWW history 3:30 – Introducing the PCR Data QuickGuide 4:20 – The circle of life of a PCR  11:00 – NEMSIS data/research license and EMS by the numbers 13:20 – Who owns PCR data 15:50 – Signatures! And legal responsibility 17:40 – Accuracy of documentation to defend your actions 18:30 – Why does the driver have to sign? 20:00 – Amending PCRs: When and why 22:33 – Who do you tell if a record is amended? 24:30 – Can your state request you to amend your PCR? 27:30 – How long should we keep documents? 30:50 – When an agency closes down or merges 33:30 – Body-worn camera content 35:30 – Transferring paper records to digital 37:15 – Bi-directional data and HIE – responsibilities 40:00 – Final thoughts Additional resources The PCR Data QuickGuide is available now, and we encourage all EMS professionals to download their copies and gain a deeper understanding of PCR data best practices. To download the guide, please follow the link: About NEMSIS About Page, Wolfberg & Wirth About our guests Ryan Stark Ryan Stark is a managing partner with Page, Wolfberg & Wirth, and is the firm's resident “HIPAA guru.”  He counsels clients on labor relations, privacy, security, reimbursement and other compliance matters affecting the ambulance industry.  Ryan started in the healthcare field as a freshman in college, where he worked for a local hospital and a retail pharmacy.  After college, he decided to become a lawyer, hoping to guide healthcare providers through the demanding legal issues they face.  He has been with PW&W since 2007, fulfilling that ambition.   Ryan is passionate about educating EMS professionals and loves collaborating with providers and CEOs alike. He is a featured speaker in PW&W seminars and webinars, including the firm's signature abc360 Conference, where he hosts the abc360 Game Show. Always enthusiastic, Ryan has been invited to speak at many state and regional EMS conferences, as well as national industry events. He is also an adjunct professor at Creighton University in the school's Master of Science in Emergency Medical Services Program.  Ryan developed, and is the primary instructor for, the nation's first and only HIPAA certification for the ambulance industry – the Certified Ambulance Privacy Officer.  He also co-authored PWW's widely used Ambulance Service Guide to HIPAA Compliance.   Ryan volunteers with local community nonprofit organizations. He was also a big brother with the Big Brothers Big Sisters program for over a decade and keeps in touch with his “little.” Ryan also enjoys hiking, running, kayaking and traveling, and spending time with son Oliver.    Steve Johnson Steve began his career in the EMS industry in 1985, gaining valuable experience while serving as an EMT and later as director of a municipal ambulance service in Minnesota. As an ambulance service manager, Steve established his expertise in areas of operations, billing and administration.   Steve also has significant EMS educational experience. He established and served as training coordinator and lead instructor for a State Certified EMS Training Institution for EMTs and First Responders.   Steve served on both the Rules Work Group and the EMS Advisory Council to the Minnesota State Department of Health. He joined the staff of a large, national billing and software company, where he was a frequent lecturer at national events and software user group programs. For over 7 years, Steve served as director of a national ambulance billing service and was responsible for all aspects of managing this company, including reimbursement, compliance and other activities for ambulance services throughout the nation. Steve served as founding executive director of the National Academy of Ambulance Coding (NAAC), overseeing all activities of the Academy, including the Certified Ambulance Coder program, the nation's only coding certification program specifically for ambulance billers and coders.   As the director of reimbursement consulting with Page, Wolfberg & Wirth, Steve is involved in all facets of the firm's consulting practice. Steve works extensively on billing and reimbursement-related activities, performing billing audits and reviews, improving billing and collections processes, providing billing and coding training, conducting documentation training programs, and performing many other services for the firm's clients across the United States.   Steve is also a licensed private pilot, and enjoys an active role in his church. Rate and review the EMS One-Stop podcast Enjoying the show? Please take a moment to rate and review us on Apple Podcasts. Contact the EMS One-Stop team at editor@EMS1.com to share ideas, suggestions and feedback.

“Money is made when you buy, not when you sell.” Is the saying for real estate investors also true for fertility doctors, their work-life balance, and their control over quality of patient care? How does an entrepreneurial fertility specialist find the REI practice equivalent to the under-priced house in the up-and-coming neighborhood? The one with unbelievably beautiful bones that isn't too much of a fixer-upper, but is just at the inflection point where its market price is about to shoot up like a hockey stick? There aren't many. Few fertility practices have already transitioned their embryology and business leadership to the same generation as the fertility doctors that will take over. But there are a couple, and we found one. Christine DeLuca and Stephen Hutchison join Griffin this week to discuss what it looks like when millennials run an REI practice. Listen to hear: How younger docs find the best value in an REI practice. What Stephen and Christine's team is doing at PCRS, that independently owned fertility practices almost never do What changes Millenials are making in the fertility practice industry- embryo storage, cryo inventory, and more. What it looks like to work in a culture where you not only help to create babies but can bring your own baby to work. Arbitrage and younger docs PS: Watch what Stephen and Christine and their team can do. Can you do this at your practice?

Welcome to the Hot Topics podcast with Dr Neal Tucker.  In this episode, we speak to Dr Katherine Hickman, current chair of the Primary Care Respiratory Society, who answers our three Just One More Thing questions on what we need to know about from primary, secondary and future care with asthma. In new research, we discuss a paper on how pharmaceutical companies spend more money promoting less effective drugs, how atropine eye drops in children can delay myopia, and whether cancer risk prediction tools are accurate in cancer survivors with their inherently raised CVD risk. www.nbmedical.com/podcast ReferencesPrimary Care Respiratory Society - if you want to know more!JAMA Drug spending on low clinical benefit drugsJAMA Atropine eye drops in kids to delay or prevent myopiaLancet CVD risk prediction tool accuracy in cancer survivors

Period Change Rates of Large Magellanic Cloud Cepheids using MESA by F. Espinoza-Arancibia et al. on Thursday 22 September Pulsating stars, such as Cepheids and RR Lyrae, offer us a window to measure and study changes due to stellar evolution. In this work, we study the former by calculating a set of evolutionary tracks of stars with an initial mass of 4 to 7 $M_odot$, varying the initial rotation rate and metallicity, using the stellar evolution code Modules for Experiments in Stellar Astrophysics (MESA). Using Radial Stellar Pulsations (RSP), a recently added functionality of MESA, we obtained theoretical instability strip (IS) edges and linear periods for the radial fundamental mode. Period-age, period-age-temperature, period-luminosity, and period-luminosity-temperature relationships were derived for three rotation rates and metallicities, showing a dependence on crossing number, position in the IS, rotation, and metallicity. We calculated period change rates (PCRs) based on the linear periods from RSP. We compared our models with literature results using the Geneva code, and found large differences, as expected due to the different implementations of rotation between codes. In addition, we compared our theoretical PCRs with those measured in our recent work for Large Magellanic Cloud Cepheids. We found good overall agreement, even though our models do not reach the short-period regime exhibited by the empirical data. Implementations of physical processes not yet included in our models, such as pulsation-driven mass loss, an improved treatment of convection that may lead to a better description of the instability strip edges, as well as consideration of a wider initial mass range, could all help improve the agreement with the observed PCRs. arXiv: http://arxiv.org/abs/http://arxiv.org/abs/2209.10609v1

At the end of each week, Mike Hosking takes you through the big ticket items and lets you know what he makes of it all. Planes and Chaos at Airports: 4/10"Because although not everything is in your control, a lot is. And enough, I suspect, to overall do better than they have.Heathrow asked airlines to stop over-selling flights. That's called greed." Covid Red Light: 6/10"Because we aren't going into it despite all the whispers.But if the school holidays don't work, stand by." RATs being Made Free: 6/10"Oh, the irony.The government that couldn't commandeer enough of them, the government that insisted PCRs were all we needed, and yet look at us now." ACT: 8/10"25 years in Parliament. That's worth celebrating." The Government's Mega Polytech Merger: 3/10"Can someone call us if they see the bloke who is supposed to be running the place?And can he tell us why they are in the hole to the extent they are?" The Government's Gang Plan: 6/10"Because it shows if you have a couple of ministers awake, you can actually do something.As opposed to pretending nothing is happening." Andrew Little: 2/10"Because it shows if you have a minister awake you can actually do something instead of pretending it's not a crisis." Number of People Leaving New Zealand: 6/10"It's not as bad as some had imagined.Yes, we are losing more people than are arriving but it wasn't a stampede." Christchurch Stadium: 8/10 "Thank God for that. Would have been a higher score if they hadn't mucked around for so long. That's the lesson here.Now head down, bum up, let's get it done." The All Blacks: 6/10."Because a loss is not the disaster or the sacking offence too many have made it out to be." LISTEN ABOVE FOR MIKE HOSKING'S FULL WEEK IN REVIEWSee omnystudio.com/listener for privacy information.

Featured Guest: Carol Stonham. Following 26 years working in general practice Carol now works at Gloucestershire CCG on the Respiratory Clinical Programme Group and runs a locality-based asthma FeNO service. Carol has also been appointed as a co-clinical lead of the NHSE South West Respiratory Network. Carol is current Executive Chair of PCRS – the first non-doctor and first female to take the chair. She is also a director of the UK Lung Cancer Coalition, and a board member of the UK Inhaler Group and National Asthma and COPD Audit as well as sitting on the NHS Long Term Plan Respiratory Delivery Board.  She also co-chairs the Lung Health Task Force early and accurate diagnosis group and is a member of the NHS Long Term Plan Breathlessness Diagnosis group. Carol received Queen's Nurse award in 2007 and in 2016 was awarded an MBE in the Queen's New Year Honours list for Services to Nursing and Healthcare.

Un jueves más, la sección más impredecible de Conocimientos Musicales nos trae un programa lleno de juegos y sorpresas varias. La primera de ellas es la aparición, por última vez esta temporada, de Guillermo Gómez, que nos vuelve a acompañar para jugar a algunas PCRs (especial música de cine) y para ejercer de juez en nuestro particular Mundial. Antes, sin embargo, la pregunta de Pau nos lleva a reflexionar sobre el trabajo individual y colectivo necesario en las orquestas para que el resultado musical sea bueno, que demuestra las diferencias que hay entre los instrumentos de cuerda y los de viento en ese aspecto. Tras las PCR, la segunda semifinal del Mundial se abre paso con un apasionante Francia-Rusia, que se baten por un puesto en la final contra Alemania.

The man recognised as the brains behind the Covid tracer app, is trying to import and trial a new type of RAT test that could be as accurate as PCRs. New Zealand experts say it could provide cheap, quick, accurate testing with far fewer false negatives, but getting it across the border isn't proving straightforward. Katie Todd reports on a RAT roadblock.

On Saturday, 16 April, violence broke out in Northwest Delhi's Jahangirpuri following a Shobha Yatra organised to mark Hanuman Jayanti. The Delhi Police have so far arrested 24 people and apprehended two juveniles in connection with communal clashes that broke out in North Delhi's Jahangirpuri after a religious Hindu procession allegedly attempted to hoist a flag on a mosque. According to the FIR filed by the police, arguments between two groups escalated after a man named Ansar came with a few people and started an argument with those participating in the yatra. The argument escalated and stone-pelting and sloganeering started from both sides. And as per purported videos of the yatra uploaded on social media and eyewitness accounts, several in the procession were carrying saffron flags, swords, pistols, and sticks. The police have also recovered three firearms and five swords from the accused persons. The Quint's reporter Fatima Khan spoke to several members of the procession and they claimed that they carried the swords for “fun”. This incident also comes days after the violence that erupted during the Ram Navami processions in several parts of the country. However, the twist in this incident is that there was a heavy deployment of police in the area where this scuffle took place. As per a report by The Indian Express, the Shobha Yatra also had police permission and around 50 police officials were deployed in Jahangirpuri along with PCRs, MVPs, and drones. Later, DCP Northwest Usha Rangani clarified that the procession took place without any permission. In today's episode, we take you through exactly what led to the violence in Jahangirpuri through eyewitness accounts and The Quint's ground reports on the same. We also speak to Somya Lakahni, Senior Editor at The Quint to know the latest on the investigation. Host and Producer: Himmat Shaligram Editor: Somya Lakhani Music: Big Bang Fuzz Listen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur

Spring Break trip to Egypt and whats the going ons of international travel post pandemic. A sneak peek at my next guest.

Este arbolito vende dólares, PCRs, vacunas pero cuando llega la policía no lo admite... --- Send in a voice message: https://anchor.fm/urbanaplayfm/message

So we're into Phase 3 as of today – and not before time. Problem is, nobody knows what any of it means. I was out all day yesterday driving around Auckland and what I can tell you is that there are still snaking queues everywhere for PCR tests. Why? Why is no one getting the memo on that? Why are all these people still queuing for tests? Possibly because RATs, which we're supposed to be doing, are so hard to find.  One of my trips yesterday involved a covert side of the road operation like a drug mule, picking up RATs I'd managed to source – at no small expense I might add – from an anonymous source who was transferring them to me from their car boot wrapped in a rubbish bag. I kid you not. It's like prohibition days – only the prohibited substance is something that should be readily available to everybody, like it is all over the rest of the world.  Why RATs aren't in every Pharmacy up and down the country by now is beyond me.  But here at Hermit Central, we're still waiting to be told when we can have stuff, where, and how. God forbid we try to adult. I was tracking down RATs because I have a family member who was a contact, and their work required a negative test before they'd let them return. Unable to get a PCR, they managed to source a single RAT kit, did the test, sent the negative result to the employer, so far so good. Except for the fact the employer said they wanted a second test result done “just to be sure”.  Now here's where it gets iffy. Employers who are unilaterally making up the rules as they go for employees make things tricky. Where were they supposed to get another RAT from? They're like hens' teeth, still no access to PCRs, and let's not forget that under the new rules, being a contact doesn't even mean you have to isolate anymore anyway unless you're in the same household as the positive case. Was the employer going to supply the RAT? No, they weren't.  Many businesses are struggling to source them too, they're having to jump through hoops and if they're not critical, they're usually falling flat on their faces. So long story short, I went into mafia mode and sourced some RATs which even if you waterboard me I'm not going to tell you where from, and I was able to supply this family member with one so they could do another test. Desperate times call for desperate measures.  The infuriating thing is why is it all so desperate when we've had all this time to get ready for this? The problem's not just the RAT access and limited availability, but also the employers who're freestyling the rules, the people who're still confused about the new contact rules, those freaked out despite the Government relaxing the rules and still wanting to 'play it safe' - and all the people just making it up as they go along. Shambles? Yes, it is.  The Government's clearly given up on this, but we're so acclimatised to rules and fear, we seemingly can't let go. If I can just say one thing to you today it's this - it's time to let it go.

Ya llevamos casi dos años de pandemia… Y de negocio. En este programa de Código de Barras hablamos del mercado de las pruebas diagnósticas, un mercado en el que se ofertan PCRs con recargo de urgencia, servicio de test a domicilio o en hotel e incluso packs familiares con descuento para un servicio que es obligatorio para, por ejemplo, viajar a otros países. Vemos por qué no se regula y qué consecuencias tendría hacerlo.Hablamos también de cupones y promociones: ¿De verdad merecen la pena? ¿Qué trampas tienen las fórmulas que utilizan para enganchar al consumidor? Intentamos entender también por qué cada vez nos hacen menos efecto los antibióticos. Para terminar, Eugenio Ribón, presidente de la Asociación Derecho de Consumo, responde a vuestras consultas.

As seleções de Camarões, Marrocos e da Nigéria foram as primeiras a garantir vaga para a próxima rodada da competição com uma rodada de antecipação. Neste domingo, jogos pelos grupos E e F encerram a segunda rodada da CAN, marcada por contrastes nos estádios, muitos deles com torcidas animadas e outros vazios, principalmente devido aos problemas ligados à Covid-19. Elcio Ramalho e Marco Martins, enviado da RFI aos Camarões Com duas vitórias nos dois primeiros jogos, camaroneses, marroquinos e e nigerianos já estão nas oitavas de final da CAN 2002. A equipe anfitriã do torneio venceu o Burkina Faso (2 a 1) na estreia e goleou a Etiópia (4 a 1) na segunda rodada, garantindo o primeiro lugar no grupo A e a classificação por antecipação.  Apesar dos resultados convincentes, o treinador português Antonio Conceição mostrou prudência sobre o desempenho da equipe de Camarões. "No plano defensivo estamos bem, e também no ataque, mas precisamos ainda melhorar para a próxima fase, que será mais difícil", disse o treinador após a goleada contra os etíopes.   Já a Nigéria também venceu os dois primeiros jogos – 1 a 0 contra o Egito e 3 a 1 sobre o Sudão – e lidera sozinha o grupo D.  No grupo C, a equipe do Marrocos também passou pelos dois primeiros adversários: 1 a 0 contra Gana e 2 a 0 contra Comores, e também já carimbou sua vaga para as oitavas da competição.  Seleções lusófonas Depois de um bom começo na primeira rodada, as duas equipes lusófonas, Guiné Bissau e Cabo Verde, perderam o segundo jogo, mas mesmo assim continuam vivas e com chances de classificação pois os quatro melhores terceiros colocados de seis grupos avançam.  Os caboverdianos estrearam com vitória de 1 a 0 sobre a Etiópia, mas perderam pelo mesmo placar para o Burkina Faso. A equipe tenta avançar para a próxima fase e para isso depende de um bom resultado contra os Camarões na última rodada da fase de grupos.  A Guiné Bissau tem um desafio ainda maior pois tem apenas um ponto na chave D, após o empate na estreia contra o Sudão. Na noite deste sábado pedeu para o Egito por 1 a 0 e precisa vencer a forte Nigéria na próxima quarta-feira (19) para brigar por uma vaga.   Contrastes nos estádios A CAN 2022 é disputada em seis estádios de cinco cidades dos Camarões, país da costa ocidental da África. Nos dois estádios em Yaoundé e em outros onde jogam seleções de países vizinhos como Nigéria e Senegal, a ocupação parcial das arquibancadas é garantida, com a presença de torcedores entusiasmados e barulhentos, vibrando ao som das vuvuzelas. No entanto, nas partidas de seleções distantes dos Camarões, como Sudão e Etiópia, por exemplo, as arquibancadas ficam geralmente vazias.  A atual pandemia de Covid-19 explica em grande parte a ausência de torcedores. Além de conseguir vistos, é preciso apresentar testes PCRs negativos para embarcar e outro de antígeno na chegada aos Camarões. Além disso, os torcedores também devem apresentar testes negativos de menos de 24 horas, no caso de antígeno, para entrar nos estádios. Para ter acesso a clínicas e laboratórios para fazer o teste é preciso passar várias horas nas longas filas.  Para os camaroneses, outra solução é apresentar um documento comprovando o esquema de vacinação completo. Mas no país, há forte resistência à campanha de vacinação.  Para ouvir o programa, clicar no link acima

France has lifted the travel restrictions for UK travellers as Omicron waves come and go. Hurrah! I hear you shout. But before you dash off to the Eurostar terminal there's still plenty to consider in regards to what you need to have to be able to travel without hassle.PCRs, LFTs and points of entry will all be discussed as I find my way to France when the travel ban is lifted, which is some time on Friday 14th January (they've not actually said when yet.)Of course this podcast is completely free, as is my weekly travel email. You can sign up at independent.co.uk/newsletters. See acast.com/privacy for privacy and opt-out information.

Testing rules: Day two PCRs scrapped for travellers arriving in UKAnalysis: The latest travel announcement is the best news we could have hoped forPolitics liveblog: Boris Johnson confirms Plan B restrictions to remain for at least three weeksScotland: Sturgeon cuts self-isolation period to seven daysEdward Colston: BLM activists who dumped statue clearedNovak Djokovic: World No1 held at Melbourne Airport after being denied entry to Australia due to visa rowBeating obesity: I learned you can't be fit and fat – when I finally lost weight by eating lessMental restoration holidays: Why you might need an emotional detoxRead all these articles and stay expertly informed anywhere, anytime with a digital subscription. Start your free one-month trial today to gain unlimited website and app access. Cancel anytime. Sign up here: https://bit.ly/3v8HLez.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

HA SIDO POSIBLE CREAR EL PROGRAMA “LA REUNIÓN SECRETA” GRACIAS A TU AYUDA COMO GUARDIÁN MECENAS. ***** HAZTE MECENAS EN HTTP://WWW.PATREON.COM/LAREUNIONSECRETA Esta noche vive el directo de #LaReuniónSecreta​ desde la 22:00,​ hora española. Te decimos lo que nadie dice: sin anestesia y sin edulcorantes. ¡La Reunión Secreta somos todos! No se lo digas a nadie… ¡PÁSALO! FUROR DOMINI: LA IRA DE DIOS La 1ª novela del Dr. Gaona que puedes comprar exclusivamente aquí: https://bit.ly/FurorDomini Conexiones en directo con: - Óscar Carreres (Profesor de odontología en la Universidad de Amsterdam - UvA) - Francisco J. Doblas Reyes (Director del Departamento de Ciencias de la Tierra del Centro Nacional de Supercomputación - BSC-CNS. Profesor en la Institución Catalana de Investigación y Estudios Avanzados - ICREA) - Fernando Montoya (Coronel del Estado Mayor. Director Internacional de Operaciones Formativas de Inteligencia y Relaciones Internacionales Security College US. Analista y Jefe de analistas en la División de Inteligencia del CIFAS (Centro de Inteligencia de las Fuerzas Armadas). Oficial de enlace español en Djibouti. Labores de Inteligencia en zonas de operaciones. Asesor militar del Embajador español, con residencia en Etiopía. Jefe de Gabinete y de Estado Mayor del General Español en la División Multinacional Salamandre en Mostar (Bosnia y Herzegovina). Manejo de las áreas de Inteligencia/Operaciones/Relaciones exteriores, con las autoridades Cívico/Militares del país al más alto nivel. Ministerio de Defensa. Asesor en Política Internacional para Magreb, Iberoamérica, África y oriente Medio) - Roberto López (Ganadero dedicado a la producción de leche con más de 25 años de experiencia en el sector. Portavoz de la Plataforma de Ganaderos Lácteos Unidos y miembro de la asociación Agromuralla) - Jorge Gómez (Exmiembro del CNI. Analista de inteligencia. https://hsintelligence.es/ ) Con el equipo habitual de La Reunión Secreta: Dr. José Miguel Gaona, Joan Miquel MJ, Carlos Martínez, Lourdes Martínez, Marta Vim y Olga Ralló. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ SÍGUENOS EN REDES Twitter: https://twitter.com/lrsecreta Instagram: https://www.instagram.com/lareunionsecreta/ Facebook: https://www.facebook.com/LRsecreta REDES SOCIALES DEL EQUIPO | DR. JOSÉ MIGUEL GAONA | - https://twitter.com/doctorgaona | DIRECTOR | - Joan Miquel MJ - https://www.instagram.com/official_joan_miquel_mj/ | PRODUCTORA | - Lourdes Martínez - https://twitter.com/chicadelaradio | AYUDANTE DE DIRECCIÓN | - Olga Ralló - https://twitter.com/olgarallo | AYUDANTE DE PRODUCCIÓN | - Carlos Martínez - https://twitter.com/Carlitos_martnz _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

113 new - now 936 cases, 9 in Nobles, 0 in ICU, Peter's newt, Find My Bus, Manx Labour on housing, rogue white lines, foreign travel PCRs & Manx nursing courses, It's Mannin Line with Andy Wint #iom #manninline #manxradio

Each week, we will be bringing you incredible tips, strategies and interviews with phenomenal medical students and residents. You can listen online (below), download it to listen later, on your smartphone: all for free.Now find us on Instagram!In this week's episode, we present our amazing colleague Aniruddha Shekara. Ani's episode was fascinating for many reasons. This interview has been long time coming , hence why we are so excited to share our conversation with Ani. Recently there has been an increased call to action for physicians that possess the wherewithal to translate research from the bench and leverage that in providing the best care to patients. This call has since been amplified due to the apparent need to enhance scientific communication proficiency in light of the kaleidoscope of opinions littered in the discourse surrounding COVID-19.  We should worry not because Ani is on the MD/PhD path. We invite you this week to witness how incredible of a person Ani is and why the future of healthcare is bright simply because he endeavors to help change the world as we know it. He shares with us the thinking behind his decision-making on switching from a premed to becoming a physician-scientist. The additional experiences he sought to make himself a competitive applicant and more were discussed. For this and many more, enjoy this week's episode!In This Week's Podcast, We'll ExploreWhy you should explore being an M.D./PhDMaking the case to justify the funding for the M.S.T.P. programBust the myth behind the M.D./Ph.D. processThe importance of research in medicineHow to seek out physician-scientist mentors How to start an independent research project as an undergradEnriching your gap years with productive experiencesAni's love for musicBooks Mentioned in the PodcastDreamland: The True Tale of America's Opiate EpidemicCrazy: A Father's Search Through America's Mental Health Madness

For those of you still recovering from yesterday's jammed-to-the-rafters-with-pop-culture-references grid, the NYTimes proudly presents as an antidote today's puzzle -- with barely a pop culture reference in sight -- thereby keeping the average number of PCRs close to the officially prescribed 3.5 PCRs per grid ... a regulation and a number that we just invented. The theme was cute, involving artificial facial components, and the rest of the clues were equally droll, including such winners as 5A, Put down in writing?, PAN, and 24A, Canine covering?, DENTALCROWN. A nice mid-week effort, we give it a 5 squares on the JAMCR scale.

A new podcast with Lyle Laverty, Former Assistant Secretary of the Interior for Fish, Wildlife and Parks, addresses mismanagement of our forests. Remember the nineteen Republican U.S. senators that helped pass the 2702-page infrastructure bill that was not read by most senators.  They sold us out!  Kabul falls into the hands of the Taliban, and Biden, Harris and Ptaski are MIA.  American personnel are told to “shelter in place.”  How is that going to work out when the Taliban is knocking on the door?  Why were so many military personnel’s lives and their families sacrificed for an ending worse than Saigon? Robyn Carnes, candidate for Centennial City Council, is concerned about local, state, national and international issues.  As a wife and a mother, she recognizes the importance of voting and that local elections have consequences.  Defunding the police will only bring more crime to all neighborhoods.  Divisiveness is rampant with the radical left's narrative.  Anytime the government gets involved there is a negative effect, including housing.  We must take a stand now or Colorado and America will be transformed permanently. Guest Pam Long, former Captain in the Army Medical Service Corps, joins Kim for a discussion on Defense Secretary Lloyd Austin's coerced recommendation that all U.S. military get the experimental drug vaccination for the COVID-19/Wuhan-China virus.  Pam states that this is a very bad policy.  Vaccinations should be voluntary and not coerced or forced for the 46% who refuse; it is actually illegal to mandate the experimental drug jab.  There are 3 exemptions for all branches of the military:  medical, including established immunity; administrative and; religious accommodation.  As an experimental drug vaccination military personnel must ask:  Does it confirm immunity?  Is it a risk when we see people are dying?  Where is the risk assessment as 99.5% survive?  Pam gives startling statistics on those who have taken the vaccination, including 12,000 deaths.  Why mandate?  Follow the money.  Billions of dollars of vaccinations and PCR tests are sitting on shelfs unused and they are all prefunded.  We all must push back on RNA vaccinations as there are many more coming down the pipeline.  The PCR test is a cash cow for institutions, including universities who are mandating the tests.  Note that the CDC has acknowledged that they cannot discriminate influenza from the coronavirus.  Also, a 24 plus cycle rate on PCRs is invalid.  Get the information you need and read.  Start with childrenshealthdefense.org. Feature Image credits: Photo By: Marine Corps Lance Cpl. Sebastian Aponte.

Vicente va a un concierto después de más de un año de confinamiento. Pasaporte sanitario, PCRs y contacto físico. Fiestas ejecutivas donde tiran el dinero por la ventana y bailan música mala. La dictadura de Macron. Daniel espera hasta el final para dar la mejor noticia hasta ahora. Música: Shoes and Socks Off, Emerald Park.

Ander Iturralde da la bienvenida a Rafa Pastrana, Nando Vila y Gonzalo Carol, además de a Cristian Colás en directo desde Wembley, para hablar de todo lo que dio de sí la primera de las dos semifinales, cómo España luchó, fue en muchos aspectos mejor y acabó, sin embargo, cayendo contra la Italia de Donnarumma, Bonucci, Chiellini, Jorginho y Chiesa; el partido, la prórroga, los penaltis y todo lo intermedio; también, los asistentes que fueron a ver el partido en directo; el Intereconomía de Estados Unidos; el fichaje de Junior Firpo por el Leeds; el de Trincao por el Wolverhampton; el estado del Barça; respondemos a las preguntas de los oyentes y mucho más.¡SUSCRÍBETE A ALINEACIÓN INDEBIDA!Escucha el podcast de Nando, "Woke Bros": https://open.spotify.com/show/5IIkaaHQ8IrRLvLjoDXnHnCanal de YouTube de Jacobin, donde Nando hace un programa los Sábados por la mañana: https://www.youtube.com/c/JacobinMag/videosSigue a Ander en Twitter: https://twitter.com/andershoffmanSigue a Nando en Twitter: https://twitter.com/nandorvilaSigue a Rafa en Twitter: https://twitter.com/RafaPastrana7Sigue a Gonzalo en Twitter: https://twitter.com/gonzalocarol29Sigue a Cristian en Twitter: https://twitter.com/crcolasEscucha el nuevo podcast de Ander en inglés sobre la afición por el fútbol: https://open.spotify.com/show/1pMTHZrH44mHPPTN2UbX3dEscucha al podcast de Diego Alonso sobre sus movidas: https://open.spotify.com/show/5cgfeRaBzA7PDNaHRtnibsEscucha el podcast de Cristian Colás, Lorenzo Manchado y Borja García sobre sus movidas: https://open.spotify.com/show/6qhIIb9wYWuT5uIEeTlexRContacto: anderpodcast@gmail.com Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Saw palmetto boosts testosterone synthesis Kyung Hee University (South Korea), June 30 2021.   The June 2021 issue of the Journal of Medicinal Food reported the finding of a beneficial effect for saw palmetto against symptoms of andropause in rats.  "Andropause, the male equivalent of menopause, is the set of symptoms caused by the age-related deficiency in male hormones that begins to occur in men in their late 40s to early 50s," Jeong Moon Yun and colleagues explained. "The symptoms of andropause include physical, psychological, and sexual problems, such as fatigue, increased body fat, decreased muscle strength and sexual function, depression, and memory loss." Dr Yun and associates evaluated the effects of an extract of saw palmetto in Leydig cells (in which testosterone biosynthesis occurs) subjected to oxidative stress and in aged rats. In Leydig cells, the administration of testosterone lowered 5 alpha-reductase (which converts testosterone to dihydrotestosterone) and increased total testosterone.  In rats, one of three doses of saw palmetto extract was administered for four weeks. A control group of animals received no treatment. At the end of the treatment period, saw palmetto supplemented rats had significantly less fat tissue weight gain and total weight gain compared to the controls, without a gain in other tissue weight. Serum triglycerides, total cholesterol and the LDL to VLDL cholesterol ratio were also lower in the supplemented groups. Serum total and free testosterone and sperm counts were higher, and sex hormone binding globulin (SHBG) and 5 alpha-reductase levels were lower in all supplemented groups in comparison with the controls. In tests of muscle endurance, rats that received saw palmetto had longer swimming times compared to the control group.  "We suggest that supplementation of saw palmetto may relieve the symptoms of andropause syndrome, including decreased spermatogenesis and muscle endurance and metabolic syndrome by increasing testosterone biosynthesis and bioavailability," the authors concluded.         Diet rich in omega 3 fatty acids may help reduce headaches Trial provides 'grounds for optimism' for many people with persistent headaches and those who care for them University of North Carolina, July 1, 2021 Eating a diet rich in omega 3 (n-3) fatty acids reduces the frequency of headaches compared with a diet with normal intake of omega 3 and omega 6 (n-6) fatty acids, finds a study published by The BMJ today. Modern industrialised diets tend to be low in omega 3 fatty acids and high in omega 6 fatty acids. These fatty acids are precursors to oxylipins - molecules involved in regulating pain and inflammation. Oxylipins derived from omega 3 fatty acids are associated with pain-reducing effects, while oxylipins derived from omega 6 fatty acids worsen pain and can provoke migraine. But previous studies evaluating omega 3 fatty acid supplements for migraine have been inconclusive. So a team of US researchers wanted to find out whether diets rich in omega 3 fatty acids would increase levels of the pain-reducing 17-hydroxydocosahexaenoic acid (17-HDHA) and reduce the frequency and severity of headaches. Their results are based on 182 patients at the University of North Carolina, USA (88% female; average age 38 years) with migraine headaches on 5-20 days per month who were randomly assigned to one of three diets for 16 weeks.  The control diet included typical levels of omega 3 and omega 6 fatty acids. Both interventional diets raised omega 3 fatty acid intake. One kept omega 6 acid intake the same as the control diet, and the other concurrently lowered omega 6 acid intake. During the trial, participants received regular dietary counseling and access to online support information. They also completed the headache impact test (HIT-6) - a questionnaire assessing headache impact on quality of life. Headache frequency was assessed daily with an electronic diary. Over the 16 weeks, both interventional diets increased 17-HDHA levels compared with the control diet, and while HIT-6 scores improved in both interventional groups, they were not statistically significantly different from the control group.  However, headache frequency was statistically significantly decreased in both intervention groups.  The high omega 3 diet was associated with a reduction of 1.3 headache hours per day and two headache days per month. The high omega 3 plus low omega 6 diet group saw a reduction of 1.7 headache hours per day and four headache days per month, suggesting additional benefit from lowering dietary omega-6 fatty acid.  Participants in the intervention groups also reported shorter and less severe headaches compared with those in the control group. This was a high quality, well designed trial, but the researchers do point to some limitations, such as the difficulty for patients to stick to a strict diet and the fact that most participants were relatively young women so results may not apply to children, older adults, men, or other populations.  "While the diets did not significantly improve quality of life, they produced large, robust reductions in frequency and severity of headaches relative to the control diet," they write.  "This study provides a biologically plausible demonstration that pain can be treated through targeted dietary alterations in humans. Collective findings suggest causal mechanisms linking n-3 and n-6 fatty acids to [pain regulation], and open the door to new approaches for managing chronic pain in humans," they conclude. These results support recommending a high omega 3 diet to patients in clinical practice, says Rebecca Burch at the Brigham and Women's Hospital, in a linked editorial. She acknowledges that interpretation of this study's findings is complex, but points out that trials of recently approved drugs for migraine prevention reported reductions of around 2-2.5 headache days per month compared with placebo, suggesting that a dietary intervention can be comparable or better.  What's more, many people with migraine are highly motivated and interested in dietary changes, she adds. These findings "take us one step closer to a goal long sought by headache patients and those who care for them: a migraine diet backed up by robust clinical trial results."     The Southern diet - fried foods and sugary drinks - may raise risk of sudden cardiac death University of Alabama, June 30, 2021  Regularly eating a Southern-style diet may increase the risk of sudden cardiac death, while routinely consuming a Mediterranean diet may reduce that risk, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association. The Southern diet is characterized by added fats, fried foods, eggs, organ meats (such as liver or giblets), processed meats (such as deli meat, bacon and hotdogs) and sugar-sweetened beverages. The Mediterranean diet is high in fruits, vegetables, fish, whole grains and legumes and low in meat and dairy. "While this study was observational in nature, the results suggest that diet may be a modifiable risk factor for sudden cardiac death, and, therefore, diet is a risk factor that we have some control over," said James M. Shikany, Dr.P.H., F.A.H.A., the study's lead author and professor of medicine and associate director for research in the Division of Preventive Medicine at the University of Alabama at Birmingham. "Improving one's diet - by eating a diet abundant in fruits, vegetables, whole grains and fish such as the Mediterranean diet and low in fried foods, organ meats and processed meats, characteristics of the Southern-style dietary pattern, may decrease one's risk for sudden cardiac death," he said. The study examined data from more than 21,000 people ages 45 and older enrolled in an ongoing national research project called REasons for Geographic and Racial Differences in Stroke (REGARDS), which is examining geographic and racial differences in stroke. Participants were recruited between 2003 and 2007. Of the participants in this analysis, 56% were women; 33% were Black adults; and 56% lived in the southeastern U.S., which is noteworthy as a region recognized as the Stroke Belt because of its higher stroke death rate. The Stroke Belt states included in this study were North Carolina, South Carolina, Georgia, Tennessee, Alabama, Mississippi, Arkansas and Louisiana. This study is the latest research to investigate the association between cardiovascular disease and diet - which foods have a positive vs. negative impact on cardiovascular disease risk. It may be the only study to-date to examine the association between dietary patterns with the risk of sudden cardiac death, which is the abrupt loss of heart function that leads to death within an hour of symptom onset. Sudden cardiac death is a common cause of death and accounted for 1 in every 7.5 deaths in the United States in 2016, or nearly 367,000 deaths, according to 2019 American Heart Association statistics. Researchers included participants with and without a history of coronary heart disease at the beginning of the study and assessed diets through a food frequency questionnaire completed at the beginning of the study. Participants were asked how often and in what quantities they had consumed 110 different food items in the previous year. Researchers calculated a Mediterranean diet score based on specific food groups considered beneficial or detrimental to health. They also derived five dietary patterns. Along with the Southern-style eating pattern, the analysis included a "sweets" dietary pattern, which features foods with added sugars, such as desserts, chocolate, candy and sweetened breakfast foods; a "convenience" eating pattern which relied on easy-to-make foods like mixed dishes, pasta dishes, or items likely to be ordered as take-out such as pizza, Mexican food and Chinese food; a "plant-based" dietary pattern was classified as being high in vegetables, fruits, fruit juices, cereal, bean, fish, poultry and yogurt; and an "alcohol and salad" dietary pattern, which was highly reliant on beer, wine, liquor along with green leafy vegetables, tomatoes and salad dressing. Shikany noted that the patterns are not mutually exclusive. "All participants had some level of adherence to each pattern, but usually adhered more to some patterns and less to others," he explained. "For example, it would not be unusual for an individual who adheres highly to the Southern pattern to also adhere to the plant-based pattern, but to a much lower degree." After an average of nearly 10 years of follow-up every six months to check for cardiovascular disease events, more than 400 sudden cardiac deaths had occurred among the 21,000 study participants. The study found: Overall, participants who ate a Southern-style diet most regularly had a 46% higher risk of sudden cardiac death than people who had the least adherence to this dietary pattern. Also, participants who most closely followed the traditional Mediterranean diet had a 26% lower risk of sudden cardiac death than those with the least adherence to this eating style. The American Heart Association's Diet and Lifestyle recommendations emphasize eating vegetables, fruits, whole grains, lean protein, fish, beans, legumes, nuts and non-tropical vegetable cooking oils such as olive and canola oil. Limiting saturated fats, sodium, added sugar and processed meat are also recommended. Sugary drinks are the number one source of added sugar in the U.S. diet, according to the Centers for Disease Control and Prevention, and the American Heart Association supports sugary drink taxes to drive down consumption of these products. "These findings support the notion that a healthier diet would prevent fatal cardiovascular disease and should encourage all of us to adopt a healthier diet as part of our lifestyles," said Stephen Juraschek, M.D., Ph.D., a member of the American Heart Association's Nutrition Committee of the Lifestyle and Cardiometabolic Health Council. "To the extent that they can, people should evaluate the number of servings of fruit and vegetables they consume each day and try to increase the number to at least 5-6 servings per day, as recommended by the American Heart Association. Optimal would be 8-9 servings per day. "This study also raises important points about health equity, food security and social determinants of health," he continued. "The authors describe the "Southern Diet" based on the U.S. geography associated with this dietary pattern, yet it would be a mistake for us to assume that this is a diet of choice. I think American society needs to look more broadly at why this type of diet is more common in the South and clusters among some racial, ethnic or socioeconomic groups to devise interventions that can improve diet quality. The gap in healthy eating between people with means and those without continues to grow in the U.S., and there is an incredible need to understand the complex societal factors that have led and continue to perpetuate these disparities." This current research expands on earlier studies on participants from the same national stroke project, REGARDS. In a 2018 analysis, Shikany and colleagues reported that adults ages 45 and older with heart disease who had an affinity for the Southern diet had a higher risk of death from any cause, while greater adherence to the Mediterranean diet was associated with a lower risk of death from any cause. And in a 2015 study, the Southern diet was linked to a greater risk of coronary heart disease in the same population. The large population sample and regional diversity, including a significant number of Black participants, are considered strengths of the REGARDS research project. However, potential limitations of this study include that that dietary intake was based on one-time, self-reported questionnaires, thus, it relied on the participants' memory. Self-reported diet can include inaccuracies leading to bias that could reduce the strength of the associations observed. One usual association that remains unexplained is that among individuals with a history of heart disease, those who most adhered to the sweets dietary pattern had a 51% lower risk of sudden cardiac death than participants who followed that pattern the least. Researchers note that they found "no viable explanation for the inverse association of the sweets dietary pattern with risk of sudden cardiac death in those with a history of coronary heart disease."     5-minute workout lowers blood pressure as much as exercise, drugs 'Strength training for breathing muscles' holds promise for host of health benefits University of Colorado, July 2, 2021 Working out just five minutes daily via a practice described as "strength training for your breathing muscles" lowers blood pressure and improves some measures of vascular health as well as, or even more than, aerobic exercise or medication, new CU Boulder research shows. The study, published June 29 in the Journal of the American Heart Association, provides the strongest evidence yet that the ultra-time-efficient maneuver known as High-Resistance Inspiratory Muscle Strength Training (IMST) could play a key role in helping aging adults fend off cardiovascular disease - the nation's leading killer.  In the United States alone, 65% of adults over age 50 have above-normal blood pressure - putting them at greater risk of heart attack or stroke. Yet fewer than 40% meet recommended aerobic exercise guidelines. "There are a lot of lifestyle strategies that we know can help people maintain cardiovascular health as they age. But the reality is, they take a lot of time and effort and can be expensive and hard for some people to access," said lead author Daniel Craighead, an assistant research professor in the Department of Integrative Physiology. "IMST can be done in five minutes in your own home while you watch TV." Developed in the 1980s as a way to help critically ill respiratory disease patients strengthen their diaphragm and other inspiratory (breathing) muscles, IMST involves inhaling vigorously through a hand-held device which provides resistance. Imagine sucking hard through a tube that sucks back.  Initially, when prescribing it for breathing disorders, doctors recommended a 30-minute-per-day regimen at low resistance. But in recent years, Craighead and colleagues have been testing whether a more time-efficient protocol--30 inhalations per day at high resistance, six days per week--could also reap cardiovascular, cognitive and sports performance improvements. For the new study, they recruited 36 otherwise healthy adults ages 50 to 79 with above normal systolic blood pressure (120 millimeters of mercury or higher). Half did High-Resistance IMST for six weeks and half did a placebo protocol in which the resistance was much lower.  After six weeks, the IMST group saw their systolic blood pressure (the top number) dip nine points on average, a reduction which generally exceeds that achieved by walking 30 minutes a day five days a week. That decline is also equal to the effects of some blood pressure-lowering drug regimens.  Even six weeks after they quit doing IMST, the IMST group maintained most of that improvement. "We found that not only is it more time-efficient than traditional exercise programs, the benefits may be longer lasting," Craighead said. The treatment group also saw a 45% improvement in vascular endothelial function, or the ability for arteries to expand upon stimulation, and a significant increase in levels of nitric oxide, a molecule key for dilating arteries and preventing plaque buildup. Nitric oxide levels naturally decline with age.  Markers of inflammation and oxidative stress, which can also boost heart attack risk, were significantly lower after people did IMST. And, remarkably, those in the IMST group completed 95% of the sessions. "We have identified a novel form of therapy that lowers blood pressure without giving people pharmacological compounds and with much higher adherence than aerobic exercise," said senior author Doug Seals, a Distinguished Professor of Integrative Physiology. "That's noteworthy." The practice may be particularly helpful for postmenopausal women. In previous research, Seals' lab showed that postmenopausal women who are not taking supplemental estrogen don't reap as much benefit from aerobic exercise programs as men do when it comes to vascular endothelial function. IMST, the new study showed, improved it just as much in these women as in men.  "If aerobic exercise won't improve this key measure of cardiovascular health for postmenopausal women, they need another lifestyle intervention that will," said Craighead. "This could be it." Preliminary results suggest MST also improved some measures of brain function and physical fitness. And previous studies from other researchers have shown it can be useful for improving sports performance. "If you're running a marathon, your respiratory muscles get tired and begin to steal blood from your skeletal muscles," said Craighead, who uses IMST in his own marathon training. "The idea is that if you build up endurance of those respiratory muscles, that won't happen and your legs won't get as fatigued." Seals said they're uncertain exactly how a maneuver to strengthen breathing muscles ends up lowering blood pressure, but they suspect it prompts the cells lining blood vessels to produce more nitric oxide, enabling them to relax. The National Institutes of Health recently awarded Seals $4 million to launch a larger follow-up study of about 100 people, comparing a 12-week IMST protocol head-to-head with an aerobic exercise program. Meanwhile, the research group is developing a smartphone app to enable people to do the protocol at home using already commercially available devices. Those considering IMST should consult with their doctor first. But thus far, IMST has proven remarkably safe, they said. "It's easy to do, it doesn't take long, and we think it has a lot of potential to help a lot of people," said Craighead.   Research suggests atheroprotective role for chrysin Fu Jen Catholic University (Taiwan), July 1, 2021 According to news reporting originating from New Taipei, Taiwan, research stated, “Atherosclerosis and its related clinical complications are the leading cause of death. MicroRNA (miR)-92a in the inflammatory endothelial dysfunction leads to atherosclerosis.” Our news editors obtained a quote from the research from Fu Jen Catholic University, “Kruppel-like factor 2 (KLF2) is required for vascular integrity and endothelial function maintenance. Flavonoids possess many biological properties. This study investigated the vascular protective effects of chrysin in balloon-injured carotid arteries. Exosomes were extracted from human coronary artery endothelial cell (HCAEC) culture media. Herb flavonoids and chrysin (found in mint, passionflower, honey and propolis) were the treatments in these atheroprotective models. Western blotting and real-time PCRs were performed. In situ hybridization, immunohistochemistry, and immunofluorescence analyses were employed. MiR-92a increased after balloon injury and was present in HCAEC culture media. Chrysin was treated, and significantly attenuated the miR-92a levels after balloon injury, and similar results were obtained in HCAEC cultures in vitro. Balloon injury-induced miR-92a expression, and attenuated KLF2 expression. Chrysin increased the KLF2 but reduced exosomal miR-92a secretion. The addition of chrysin and antagomir-92a, neointimal formation was reduced by 44.8 and 49.0% compared with balloon injury after 14 days, respectively. Chrysin upregulated KLF2 expression in atheroprotection and attenuated endothelial cell-derived miR-92a-containing exosomes.” According to the news editors, the research concluded: “The suppressive effect of miR-92a suggests that chrysin plays an atheroprotective role.” This research has been peer-reviewed.     False-positive mammogram results linked to spike in anxiety prescriptions Penn State University, July 2, 2021 Women who experience a false-positive mammogram result are more likely to begin medication for anxiety or depression than women who received an immediate negative result, according to a study led by Penn State researcher Joel Segel. The finding highlights the importance of swift and accurate follow-up testing to rule out a breast cancer diagnosis. The study found that patients who receive a false-positive mammogram result are also prescribed anxiety or depression medication at a rate 10 to 20 percent higher than patients who receive an immediate negative result. These prescriptions are new and not continuations of previously prescribed medicines. A false-positive result is one where a suspicious finding on the screening mammogram leads to additional testing that does not end up leading to a breast cancer diagnosis. Additionally, within that group of patients who required more than one test to resolve the false-positive there was a 20 to 30 percent increase in those beginning to take anxiety or depression medications. The increase was particularly noticeable among women with commercial insurance who required multiple tests to rule out a breast cancer diagnosis. "The results suggest that efforts to quickly resolve initially positive findings including same-day follow-up tests may help reduce anxiety and even prevent initiation of anxiety or depression medication," said Segel, assistant professor of health policy and administration at Penn State. This study demonstrates that some women who experience a false-positive mammogram may need additional follow-up care to effectively handle the increased anxiety that may accompany the experience, Segel said. More importantly, from a practitioner standpoint, the study identifies sub-populations who may be most at risk of increased anxiety following a false-positive mammogram, Segel said. Specifically, women whose false-positive result requires more than one follow-up test to resolve, women with commercial insurance who undergo a biopsy, women who wait longer than one week to receive a negative result, and women who are under age 50 may all be at higher risk of experiencing clinically significant anxiety or depression. "Regular breast cancer screening is critical to early detection," Segel said. "Patients should continue to work with their providers to ensure they are receiving guideline-appropriate screening and should follow up with their providers if they experience either anxiety or depression following screening or any type of care." Researchers studied commercial- and Medicaid-claims databases to identify women ages 40 to 64 who underwent screening mammography with no prior claims for anxiety or depression medications. The findings recently appeared in Medical Care.     Thymoquinone in Black Seed oil increases the expression of neuroprotective proteins while decreasing expression of pro-inflammatory cytokines Florida A&M University, June 29, 2021    According to news originating from Tallahassee, Florida, research stated, "Neuroinflammation and microglial activation are pathological markers of a number of central nervous system (CNS) diseases. Chronic activation of microglia induces the release of excessive amounts of reactive oxygen species (ROS) and pro-inflammatory cytokines." Our news journalists obtained a quote from the research from Florida A&M University, "Additionally, chronic microglial activation has been implicated in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Thymoquinone (TQ) has been identified as one of the major active components of the natural product Nigella sativa seed oil. TQ has been shown to exhibit anti-inflammatory, anti-oxidative, and neuroprotective effects. In this study, lipopolysaccharide (LPS) and interferon gamma (IFN gamma) activated BV-2 microglial cells were treated with TQ (12.5 mu M for 24 h). We performed quantitative proteomic analysis using Orbitrap/Q-Exactive Proteomic LC-MS/MS (Liquid chromatography-mass spectrometry) to globally assess changes in protein expression between the treatment groups. Furthermore, we evaluated the ability of TQ to suppress the inflammatory response using ELISArray ™ for Inflammatory Cytokines. We also assessed TQ's effect on the gene expression of NFKB signaling targets by profiling 84 key genes via real-time reverse transcription (RT2) PCR array. Our results indicated that TQ treatment of LPS/IFN gamma-activated microglial cells significantly increased the expression of 4 antioxidant, neuroprotective proteins: glutaredoxin-3 (21 fold; p< 0.001), biliverdin reductase A (15 fold; p< 0.0001), 3-mercaptopyruvate sulfurtransferase (11 fold; p< 0.01), and mitochondria] Ion protease (> 8 fold; p< 0.001) compared to the untreated, activated cells. Furthermore, TQ treatment significantly (P < 0.0001) reduced the expression of inflammatory cytokines, IL-2 = 38%, IL-4 = 19%, IL-6 = 83%, IL-10 = 237%, and IL-17a = 29%, in the activated microglia compared to the untreated, activated which expression levels were significantly elevated compared to the control microglia: IL-2 = 127%, IL-4 = 151%, IL-6 = 670%, IL-10 = 133%, IL-17a = 127%. Upon assessing the gene expression of NFKB signaling targets, this study also demonstrated that TQ treatment of activated microglia resulted in > 7 fold down-regulation of several NFKB signaling targets genes, including interleukin 6 (IL6), complement factor B (CFB), chemokine (C-C motif) ligand 3 (CXCL3), chemokine (C-C) motif ligand 5 (CCL5) compared to the untreated, activated microglia. This modulation in gene expression counteracts the > 10-fold upregulation of these same genes observed in the activated microglia compared to the controls. Our results show that TQ treatment of LPS/IFN gamma-activated BV-2 microglial cells induce a significant increase in expression of neuroprotective proteins, a significant decrease in expression inflammatory cytokines, and a decrease in the expression of signaling target genes of the NF kappa B pathway. Our findings are the first to show that TQ treatment increased the expression of these neuroprotective proteins (biliverdin reductase-A, 3-mercaptopyruvate sulfurtransferase, glutaredoxin-3, and mitochondrial Ion protease) in the activated BV-2 microglial cells. Additionally, our results indicate that TQ treatment decreased the activation of the NF kappa B signaling pathway, which plays a key role in neuroinflammation." According to the news editors, the research concluded: "Our results demonstrate that TQ treatment reduces the inflammatory response and modulates the expression of specific proteins and genes and hence potentially reduce neuroinflammation and neurodegeneration driven by microglial activation."

En este nuevo programa de Sexo y lo que surja estamos ya un poco cansados de tanto hablar, es verano y necesitamos vacaciones, además hasta nosotros estamos cansados de oírnos, así que hemos preferido escucharos a vosotros. Escuchamos y comentamos los audios tan divertidos que nos habéis mandado y hablamos sobre el semen en la cara, qué consideramos cuernos, las orgías que te saltan a la cara o cuando besas a una persona de tu sexo a causa de la cerveza. Al final en todos sitios cuecen habas (ya podían ser garbanzos) y todos tenemos historias que contar, qué bien hacerlo juntos. En el cajón encontramos un aparatito que al principio pensábamos que era para hacer PCRs, pero al metérselo Juanma por la nariz ha descubierto el gustito que daba su vibración en los piercings, le ha durado poco, Aza ha dicho que pa chulo su chumino y que eso se quedaba en su coño por los siglos de los siglos, amén. Como seguimos sin querer trabajar pues nos recreamos en los minutos de la basura, que son como charlar por zoom con un colega, pero grabando. No podía faltar nuestras expectativas sobre el Numancia, los planes para el finde o fingir que has quedado con más gente para pedir más pizza. 🎧Regístrate aquí para conseguir una historia gratis en Audiodesires: https://audiodesires.com/es/registro/?utm_campaign=sexosurja. 🎀Programa patrocinado por Bijoux Indiscrets https://shopes.bijouxindiscrets.com/ 🧡Dale LIKE🧡 Síguenos en: ➡️Instagram: https://www.instagram.com/sexoyloquesurja2021 ➡️Twitter: https://twitter.com/sexoyloquesurja ➡️Web: https://sexoyloquesurja.com/ ➡️Twitch: https://www.twitch.tv/sexoyloquesurja ➡️Facebook: https://www.facebook.com/seyloque/ 🍆Reserva tu TupperSex en: https://sexoyloquesurja.com/tupper/ o en tupper@sexoyloquesurja.com 💸Ayúdanos a financiar el proyecto en: https://www.patreon.com/sexoyloquesurja 📧Y puedes contactar con nosotros en: sexoyloquesurjablog@gmail.com

Analitzem la nova escalada de contagis de Covid i la situaci

Analitzem la nova escalada de contagis de Covid i la situaci

Editorial de Edgardo Chini

I speak with Australian dot-connector Max Igan about questioning the super-narrative, the deeper agenda, internet censorship, the subjective nature of misinformation, COVID “vaccine” as experiment, the Mainframe, the mudflood, the Lucifer System, information vs. wisdom, and the inaccuracy of PCRs. Max’s website: https://thecrowhouse.com/home.html To support The Melt with a monthly subscription fee as low as... Read More